uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.1183 | Q17 | What gene does the drug Erenumab target? | The drug Erenumab targets the gene CALCRL. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%erenumab%" OR LOWER(tradeNames_string) LIKE "%erenumab%" OR LOWER(drugSynonyms_string) LIKE "%erenumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5361', 'drugName': 'Erenumab', 'tradeNames_string': 'Aimovig', 'drugSynonyms_string': 'AMG 334, AMG-334, Erenumab, Erenumab aooe, Erenumab-aooe', 'linkedDiseasesDrug_string': 'Temporomandibular Joint Disorder (EFO_0005279), Angina Pectoris (EFO_0003913), Migraine Disorder (MONDO_0005277), Trigeminal Neuralgia (EFO_1001219), Neuropathy (EFO_0004149)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCRL (ENSG00000064989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1333 | Q17 | What gene does the drug Mra 003 Us target? | The drug Mra 003 Us is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mra 003 us%" OR LOWER(tradeNames_string) LIKE "%mra 003 us%" OR LOWER(drugSynonyms_string) LIKE "%mra 003 us%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3613', 'drugName': 'Mra 003 Us', 'tradeNames_string': '', 'drugSynonyms_string': 'MRA 003 US, Mra 003 us', 'linkedDiseasesDrug_string': 'Systemic Lupus Erythematosus (MONDO_0007915)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL6 (ENSG00000136244)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1806 | Q17 | What gene does the drug Eflepedocokin Alfa target? | The drug Eflepedocokin Alfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: IL22RA1 and IL10RB | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eflepedocokin alfa%" OR LOWER(tradeNames_string) LIKE "%eflepedocokin alfa%" OR LOWER(drugSynonyms_string) LIKE "%eflepedocokin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6267', 'drugName': 'Eflepedocokin Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'Eflepedocokin alfa, F 652, F-652, Il-22 dimer f-652, Promenakin', 'linkedDiseasesDrug_string': 'Hepatitis, Alcoholic (EFO_1001345), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL10RB (ENSG00000243646), IL22RA1 (ENSG00000142677)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1819 | Q17 | What gene does the drug Secretin Synthetic Human target? | The drug Secretin Synthetic Human targets the gene SCTR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%secretin synthetic human%" OR LOWER(tradeNames_string) LIKE "%secretin synthetic human%" OR LOWER(drugSynonyms_string) LIKE "%secretin synthetic human%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4712', 'drugName': 'Secretin Synthetic Human', 'tradeNames_string': 'Chirhostim', 'drugSynonyms_string': 'Human secretin, Secretin (human), Secretin (human), acetate (salt), Secretin Synthetic Human, Secretin acetate human, Secretin human, Secretin human acetate, Secretin human pentaacetate, Secretin synthetic human, Synthetic human secretin', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Obsessive-Compulsive Disorder (EFO_0004242)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCTR (ENSG00000080293)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1374 | Q17 | What gene does the drug Fingolimod Lauryl Sulfate target? | The drug Fingolimod Lauryl Sulfate targets 5 genes: S1PR3, S1PR4, S1PR5, S1PR1 and S1PR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fingolimod lauryl sulfate%" OR LOWER(tradeNames_string) LIKE "%fingolimod lauryl sulfate%" OR LOWER(drugSynonyms_string) LIKE "%fingolimod lauryl sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5906', 'drugName': 'Fingolimod Lauryl Sulfate', 'tradeNames_string': 'Tascenso odt', 'drugSynonyms_string': 'Fingolimod lauryl sulfate, Tascenso', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1144 | Q17 | What gene does the drug Dothiepin target? | The drug Dothiepin targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dothiepin%" OR LOWER(tradeNames_string) LIKE "%dothiepin%" OR LOWER(drugSynonyms_string) LIKE "%dothiepin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4896', 'drugName': 'Dothiepin', 'tradeNames_string': '', 'drugSynonyms_string': 'Dosulepin, Dothiepin, Dothirpin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4897', 'drugName': 'Dothiepin', 'tradeNames_string': '', 'drugSynonyms_string': 'Dosulepin, Dothiepin, Dothirpin', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.367 | Q17 | What gene does the drug De-104 target? | The drug De-104 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: ROCK2 and ROCK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%de-104%" OR LOWER(tradeNames_string) LIKE "%de-104%" OR LOWER(drugSynonyms_string) LIKE "%de-104%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3818', 'drugName': 'De-104', 'tradeNames_string': '', 'drugSynonyms_string': 'De-104', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Ocular Hypertension (EFO_1001069)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ROCK2 (ENSG00000134318), ROCK1 (ENSG00000067900)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1790 | Q17 | What gene does the drug Galcanezumab target? | The drug Galcanezumab targets 2 genes: CALCB and CALCA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%galcanezumab%" OR LOWER(tradeNames_string) LIKE "%galcanezumab%" OR LOWER(drugSynonyms_string) LIKE "%galcanezumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1901', 'drugName': 'Galcanezumab', 'tradeNames_string': 'Emgality', 'drugSynonyms_string': 'Galcanezumab, Galcanezumab gnlm, Galcanezumab-gnlm, LY-2951742, LY2951742', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCA (ENSG00000110680), CALCB (ENSG00000175868)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1208 | Q17 | What gene does the drug Dutetrabenazine target? | The drug Dutetrabenazine targets the gene SLC18A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%dutetrabenazine%" OR LOWER(tradeNames_string) LIKE "%dutetrabenazine%" OR LOWER(drugSynonyms_string) LIKE "%dutetrabenazine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1735', 'drugName': 'Dutetrabenazine', 'tradeNames_string': 'Austedo', 'drugSynonyms_string': 'Deutetrabenazine, Dutetrabenazine, SD-809', 'linkedDiseasesDrug_string': 'Cerebral Palsy (EFO_1000632), Tourette Syndrome (EFO_0004895), Movement Disorder (EFO_0004280), Huntington Disease (MONDO_0007739), Chorea (EFO_0004152), Dystonic Disorder (MONDO_0003441)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC18A2 (ENSG00000165646)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1035 | Q17 | What gene does the drug Botulinum Toxin Type B target? | The drug Botulinum Toxin Type B targets the gene VAMP2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%botulinum toxin type b%" OR LOWER(tradeNames_string) LIKE "%botulinum toxin type b%" OR LOWER(drugSynonyms_string) LIKE "%botulinum toxin type b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6024', 'drugName': 'Botulinum Toxin Type B', 'tradeNames_string': 'Myobloc, Neurobloc', 'drugSynonyms_string': 'AN-0772, Botulin b, Botulinum toxin type b', 'linkedDiseasesDrug_string': 'Skin Ulcer (HP_0200042), Cerebral Palsy (EFO_1000632), Carpal Tunnel Syndrome (EFO_0004143), Drooling (HP_0002307), Dementia (HP_0000726), Torticollis (HP_0000473), Hyperhidrosis (HP_0000975), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'VAMP2 (ENSG00000220205)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1039 | Q17 | What gene does the drug Cdx-3379 target? | The drug Cdx-3379 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ERBB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cdx-3379%" OR LOWER(tradeNames_string) LIKE "%cdx-3379%" OR LOWER(drugSynonyms_string) LIKE "%cdx-3379%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1385', 'drugName': 'Cdx-3379', 'tradeNames_string': '', 'drugSynonyms_string': 'CDX-3379, Cdx 3379, Cdx-3379, Cdx3379, KTN-3379, MEDI-3379', 'linkedDiseasesDrug_string': 'Melanoma (EFO_0000756), Head And Neck Squamous Cell Carcinoma (EFO_0000181)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1761 | Q17 | What gene does the drug Eptifibatide target? | The drug Eptifibatide targets 2 genes: ITGB3 and ITGA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eptifibatide%" OR LOWER(tradeNames_string) LIKE "%eptifibatide%" OR LOWER(drugSynonyms_string) LIKE "%eptifibatide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1804', 'drugName': 'Eptifibatide', 'tradeNames_string': 'Eptifibatide, Integrilin', 'drugSynonyms_string': 'Eptifibatide, Integrelin', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Coronary Artery Disease (EFO_0001645), Ischemic Stroke (HP_0002140), Pneumonia (EFO_0003106), Septic Shock (EFO_0006834), Stroke (EFO_0000712), Sickle Cell Anemia (MONDO_0011382), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612), Acute Myocardial Infarction (EFO_0008583), Acute Coronary Syndrome (EFO_0005672), St Elevation Myocardial Infarction (EFO_0008585), Brain Infarction (EFO_0004277)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ITGB3 (ENSG00000259207), ITGA2B (ENSG00000005961)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1357 | Q17 | What gene does the drug Lidocaine Hydrochloride target? | The drug Lidocaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lidocaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%lidocaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%lidocaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4126', 'drugName': 'Lidocaine Hydrochloride', 'tradeNames_string': 'Akten, Alphacaine hydrochloride, Anestacon, Anodesyn, Bismodyne, Bradosol plus, Calgel, Co-phenylcaine fte, Denela, Dequaspray, Emla, Germoloids, Germoloids complete, Glydo, Hemocane, Iglu, Instillagel, Laryng-o-jet kit, Laryngojet, Laryngotracheal anesthesia kit, Lido hcl, Lidocaine hydrochloride, Lidocaine hydrochloride preservative free, Lidocaine hydrochloride viscous, Lidocaine viscous, Lidocaton, Lidopen, Lignokent, Lignospan special, Lignostab, Lignostab a 100, Lignostab n, Lignostab-a, Lta ii kit, Medijel, Oragard, Pediatric lta kit, Preparation h, Rexocaine, Versatis, Xylocaine, Xylocaine dental, Xylocaine preservative free, Xylocaine viscous, Xylotox e80, Zingo', 'drugSynonyms_string': 'Anhydrous lidocaine hydrochloride, Lidocaine hcl, Lidocaine hydrochloride, Lidocaine hydrochloride anhydrous, Lidocaine hydrochloride monohydrate, Lidocaine hydrochloride usp, Lidocaini hydrochloridum, Lignocaine (as hydrochloride), Lignocaine hydrochloride, NSC-757420, Xylocaine hydrochloride', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Cancer (MONDO_0004992), Migraine Disorder (MONDO_0005277), Pain (EFO_0003843), Injury (EFO_0000546), Pregnancy (EFO_0002950), Prostate Carcinoma (EFO_0001663), Headache (HP_0002315), Rotator Cuff Tear (EFO_1001250), Thalassemia (EFO_1001996), Hypertension (EFO_0000537), Pruritus (HP_0000989), Pancreatic Carcinoma (EFO_0002618), Hemorrhoid (EFO_0009552), Spinal Stenosis (EFO_0007490), Back Pain (HP_0003418), Liver Cancer (MONDO_0002691), Chronic Pain (HP_0012532), Mucositis (EFO_1001898)', 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1875 | Q17 | What gene does the drug Belatacept target? | The drug Belatacept targets 2 genes: CD80 and CD86. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%belatacept%" OR LOWER(tradeNames_string) LIKE "%belatacept%" OR LOWER(drugSynonyms_string) LIKE "%belatacept%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4093', 'drugName': 'Belatacept', 'tradeNames_string': 'Nujolix, Nulojix', 'drugSynonyms_string': 'BMS-224818, Belatacept, LEA29Y', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Proteinuria (HP_0000093), Rheumatoid Arthritis (EFO_0000685), Acute Graft Vs. Host Disease (EFO_0004599), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD80 (ENSG00000121594), CD86 (ENSG00000114013)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4094', 'drugName': 'Belatacept', 'tradeNames_string': 'Nujolix, Nulojix', 'drugSynonyms_string': 'BMS-224818, Belatacept, LEA29Y', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Proteinuria (HP_0000093), Rheumatoid Arthritis (EFO_0000685), Acute Graft Vs. Host Disease (EFO_0004599), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 2011, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD80 (ENSG00000121594), CD86 (ENSG00000114013)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.672 | Q17 | What gene does the drug Acadesine target? | The drug Acadesine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: PRKAB1, PRKAA2, PRKAA1, PRKAB2, PRKAG1, PRKAG2 and PRKAG3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acadesine%" OR LOWER(tradeNames_string) LIKE "%acadesine%" OR LOWER(drugSynonyms_string) LIKE "%acadesine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5888', 'drugName': 'Acadesine', 'tradeNames_string': '', 'drugSynonyms_string': 'Acadesine, GP-1-110, NSC-105823', 'linkedDiseasesDrug_string': 'Chronic Lymphocytic Leukemia (EFO_0000095), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PRKAA2 (ENSG00000162409), PRKAB2 (ENSG00000131791), PRKAG1 (ENSG00000181929), PRKAG2 (ENSG00000106617), PRKAB1 (ENSG00000111725), PRKAA1 (ENSG00000132356), PRKAG3 (ENSG00000115592)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.369 | Q17 | What gene does the drug Betamethasone Dipropionate target? | The drug Betamethasone Dipropionate targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%betamethasone dipropionate%" OR LOWER(tradeNames_string) LIKE "%betamethasone dipropionate%" OR LOWER(drugSynonyms_string) LIKE "%betamethasone dipropionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6021', 'drugName': 'Betamethasone Dipropionate', 'tradeNames_string': 'Alphatrex, Betamethasone dipropionate, Diprolene, Diprolene af, Diprosone, Sernivo', 'drugSynonyms_string': 'Betamethasone (as dipropionate), Betamethasone 17,21-dipropionate, Betamethasone dipropionate, Diprospan, Maxivate, NSC-758415, Rinderon dp, SCH 11460, SCH-11460', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Sinusitis (EFO_0007486), Infection (EFO_0000544), Oral Lichen Planus (EFO_0008517), Hemorrhoid (EFO_0009552), Eye Inflammation (EFO_0005752), Atopic Eczema (EFO_0000274), Airway Obstruction (HP_0006536), Skin Disease (EFO_0000701), Periarthritis (EFO_1001097), Nasal Congestion (HP_0001742), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.80 | Q17 | What gene does the drug Gusacitinib target? | The drug Gusacitinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: JAK3, JAK1, JAK2, SYK and TYK2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gusacitinib%" OR LOWER(tradeNames_string) LIKE "%gusacitinib%" OR LOWER(drugSynonyms_string) LIKE "%gusacitinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2273', 'drugName': 'Gusacitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ASN-002, ASN002, Asn-002, Asn002, EN-3351, EN3351, Gusacitinib', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Atopic Eczema (EFO_0000274), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_2274', 'drugName': 'Gusacitinib', 'tradeNames_string': '', 'drugSynonyms_string': 'ASN-002, ASN002, Asn-002, Asn002, EN-3351, EN3351, Gusacitinib', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Atopic Eczema (EFO_0000274), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SYK (ENSG00000165025), JAK3 (ENSG00000105639), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), TYK2 (ENSG00000105397)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.28 | Q17 | What gene does the drug Iproniazid target? | The drug Iproniazid targets 2 genes: MAOB and MAOA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%iproniazid%" OR LOWER(tradeNames_string) LIKE "%iproniazid%" OR LOWER(drugSynonyms_string) LIKE "%iproniazid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1751', 'drugName': 'Iproniazid', 'tradeNames_string': 'Marsilid', 'drugSynonyms_string': 'Iproniazid, Iproniazide', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOA (ENSG00000189221), MAOB (ENSG00000069535)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1438 | Q17 | What gene does the drug Tretinoin target? | The drug Tretinoin targets 3 genes: RARB, RARA and RARG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tretinoin%" OR LOWER(tradeNames_string) LIKE "%tretinoin%" OR LOWER(drugSynonyms_string) LIKE "%tretinoin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5360', 'drugName': 'Tretinoin', 'tradeNames_string': 'Acticin, Altreno, Atralin, Avita, Renova, Retin-a, Retin-a micro, Retin-a-micro, Tretin-X, Tretinoin, Vesanoid', 'drugSynonyms_string': 'Aberel, All-trans retinoic acid, All-trans-retinoic acid, Eudyna, Kerlocal, NSC-122758, Oristar rna, Retin a, Retinoic acid, Tretinoin', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Rosacea (EFO_1000760), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Covid-19 (MONDO_0100096), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Adenoid Cystic Carcinoma (EFO_0000231), Myelodysplastic Syndrome (EFO_0000198), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Freckles (EFO_0003963), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Basal Cell Carcinoma (EFO_0004193), Acne (EFO_0003894), Emphysema (EFO_0000464), Pancreatic Carcinoma (EFO_0002618), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Small Cell Lung Carcinoma (EFO_0000702), Actinic Keratosis (EFO_0002496), Hypercholesterolemia (HP_0003124), Anemia (MONDO_0002280), Cutaneous Melanoma (EFO_0000389), Autoimmune Thrombocytopenia (MONDO_0019098), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Amyotrophic Lateral Sclerosis (MONDO_0004976), Squamous Cell Carcinoma (EFO_0000707), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Myeloproliferative Disorder (EFO_0004251), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Sclerosing Cholangitis (EFO_0004268), Lentigo (MONDO_0021582), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Striae Distensae (HP_0001065)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_3116', 'drugName': 'Isotretinoin', 'tradeNames_string': 'Absorica, Absorica ld, Accutane, Amnesteem, Claravis, Isotrex, Myorisan, Roaccutane, Sotret, Zenatane', 'drugSynonyms_string': '13 Cis-Retinoic Acid, 13-cis-retinoic acid, Isotretinoin, NSC-758156, PAT-001, RO 4-3780, RO-4-3780, RO-43780, Retinoic acid 13-cis-form, Retinoic acid, 13-cis-, Vitamin a acid, 13-cis', 'linkedDiseasesDrug_string': "Neuroblastoma (EFO_0000621), Multiple Myeloma (EFO_0001378), Alzheimer Disease (MONDO_0004975), Medulloblastoma (EFO_0002939), Infection (EFO_0000544), Rosacea (EFO_1000760), Mixed Glioma (MONDO_0003268), Covid-19 (MONDO_0100096), Oligodendroglioma (EFO_0000632), Azoospermia (EFO_0000279), Klinefelter'S Syndrome (EFO_1001006), Burkitts Lymphoma (EFO_0000309), Myelodysplastic Syndrome (EFO_0000198), Focal Segmental Glomerulosclerosis (EFO_0004236), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Acute Promyelocytic Leukemia (EFO_0000224), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Tinea Pedis (EFO_0007512), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Acute Myeloid Leukemia (EFO_0000222), Wilms Tumor (MONDO_0006058), Mycosis Fungoides (EFO_1001051), Acne (EFO_0003894), Emphysema (EFO_0000464), Diffuse Large B-Cell Lymphoma (EFO_0000403), Central Nervous System Neoplasm (EFO_1000158), Anaplastic Oligodendroglioma (EFO_0002501), Ganglioneuroblastoma (EFO_0000502), Actinic Keratosis (EFO_0002496), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Hiv-1 Infection (EFO_0000180), Brain Neoplasm (EFO_0003833), Dysplasia Of Cervix (EFO_1000910), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Head And Neck Malignant Neoplasia (EFO_0006859), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Kidney Cancer (MONDO_0002367), Ichthyosis (MONDO_0019269), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519)", 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RARG (ENSG00000172819), RARB (ENSG00000077092), RARA (ENSG00000131759)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_701', 'drugName': 'Alitretinoin', 'tradeNames_string': 'Panretin, Toctino', 'drugSynonyms_string': '9-cis retinoic acid, 9-cis-retinoic acid, AGN 192013, AGN-192013, ALRT-1057, ALRT1057, Alitretinoin, BAL-4079, LG-100057, LG100057, LGD-1057, LGD1057, NSC-659772, Panretin, Retinoic acid 9-cis-form', 'linkedDiseasesDrug_string': 'Eczema (HP_0000964), Psoriasis (EFO_0000676), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Lichen Planus (EFO_1000726), Hand Dermatosis (EFO_1000706), Cutaneous Lupus Erythematosus (EFO_0003834)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'RXRB (ENSG00000204231), RARG (ENSG00000172819), RXRG (ENSG00000143171), RARB (ENSG00000077092), RARA (ENSG00000131759), RXRA (ENSG00000186350)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.531 | Q17 | What gene does the drug Ergoloid Mesylates target? | The drug Ergoloid Mesylates targets 13 genes: ADRA2A, DRD4, DRD1, ADRA2C, DRD3, HTR1B, ADRA1D, ADRA1B, HTR1A, DRD2, DRD5, ADRA2B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ergoloid mesylates%" OR LOWER(tradeNames_string) LIKE "%ergoloid mesylates%" OR LOWER(drugSynonyms_string) LIKE "%ergoloid mesylates%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3520', 'drugName': 'Ergoloid Mesylates', 'tradeNames_string': 'Alkergot, Circanol, Deapril, Deapril-st, Ergoloid mesylates, Gerimal, Hydergine, Hydergine lc, Hydrogenated ergot alkaloids', 'drugSynonyms_string': 'Co-dergocrine mesilate, Co-dergocrine mesylate, Codergocrine mesilate, Dihydroergotoxine mesilate, Dihydroergotoxine mesylate, Dihydroergotoxine methanesulfonate, Dihydrogenated ergot alkaloids, Ergoloid mesilates, Ergoloid mesylates, Hydrogenated ergot alkaloids', 'linkedDiseasesDrug_string': 'Fragile X Syndrome (MONDO_0010383), Cardiovascular Disease (EFO_0000319), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1A (ENSG00000178394), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 13}, {'UUID': 'DrugGeneTargets_v2_3519', 'drugName': 'Ergoloid Mesylates', 'tradeNames_string': 'Alkergot, Circanol, Deapril, Deapril-st, Ergoloid mesylates, Gerimal, Hydergine, Hydergine lc, Hydrogenated ergot alkaloids', 'drugSynonyms_string': 'Co-dergocrine mesilate, Co-dergocrine mesylate, Codergocrine mesilate, Dihydroergotoxine mesilate, Dihydroergotoxine mesylate, Dihydroergotoxine methanesulfonate, Dihydrogenated ergot alkaloids, Ergoloid mesilates, Ergoloid mesylates, Hydrogenated ergot alkaloids', 'linkedDiseasesDrug_string': 'Fragile X Syndrome (MONDO_0010383), Cardiovascular Disease (EFO_0000319), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1A (ENSG00000178394), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 13}, {'UUID': 'DrugGeneTargets_v2_3522', 'drugName': 'Ergoloid Mesylates', 'tradeNames_string': 'Alkergot, Circanol, Deapril, Deapril-st, Ergoloid mesylates, Gerimal, Hydergine, Hydergine lc, Hydrogenated ergot alkaloids', 'drugSynonyms_string': 'Co-dergocrine mesilate, Co-dergocrine mesylate, Codergocrine mesilate, Dihydroergotoxine mesilate, Dihydroergotoxine mesylate, Dihydroergotoxine methanesulfonate, Dihydrogenated ergot alkaloids, Ergoloid mesilates, Ergoloid mesylates, Hydrogenated ergot alkaloids', 'linkedDiseasesDrug_string': 'Fragile X Syndrome (MONDO_0010383), Cardiovascular Disease (EFO_0000319), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1A (ENSG00000178394), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 13}, {'UUID': 'DrugGeneTargets_v2_3521', 'drugName': 'Ergoloid Mesylates', 'tradeNames_string': 'Alkergot, Circanol, Deapril, Deapril-st, Ergoloid mesylates, Gerimal, Hydergine, Hydergine lc, Hydrogenated ergot alkaloids', 'drugSynonyms_string': 'Co-dergocrine mesilate, Co-dergocrine mesylate, Codergocrine mesilate, Dihydroergotoxine mesilate, Dihydroergotoxine mesylate, Dihydroergotoxine methanesulfonate, Dihydrogenated ergot alkaloids, Ergoloid mesilates, Ergoloid mesylates, Hydrogenated ergot alkaloids', 'linkedDiseasesDrug_string': 'Fragile X Syndrome (MONDO_0010383), Cardiovascular Disease (EFO_0000319), Vascular Dementia (EFO_0004718)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1A (ENSG00000178394), ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD5 (ENSG00000169676), DRD4 (ENSG00000069696), DRD1 (ENSG00000184845)', 'numberLinkedTargets': 13}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1836 | Q17 | What gene does the drug Eplerenone target? | The drug Eplerenone targets the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eplerenone%" OR LOWER(tradeNames_string) LIKE "%eplerenone%" OR LOWER(drugSynonyms_string) LIKE "%eplerenone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4937', 'drugName': 'Eplerenone', 'tradeNames_string': 'Eplerenone, Inspra', 'drugSynonyms_string': 'Eplerenone, SC-66110, SC-6611O', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Congestive Heart Failure (EFO_0000373), Breast Cancer (MONDO_0007254), Diabetic Nephropathy (EFO_0000401), Central Serous Retinopathy (EFO_0009784), Primary Hyperparathyroidism (EFO_0008519), Duchenne Muscular Dystrophy (MONDO_0010679), Heart Failure (EFO_0003144), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612), Cardiovascular Disease (EFO_0000319), Stroke (EFO_0000712), Essential Hypertension (MONDO_0001134), Type 2 Diabetes Mellitus (MONDO_0005148), Cardiomyopathy (EFO_0000318), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.56 | Q17 | What gene does the drug Zandelisib target? | The drug Zandelisib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PIK3CD. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zandelisib%" OR LOWER(tradeNames_string) LIKE "%zandelisib%" OR LOWER(drugSynonyms_string) LIKE "%zandelisib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5341', 'drugName': 'Zandelisib', 'tradeNames_string': '', 'drugSynonyms_string': 'ACC-524, ME-401, Me-401, PW-143, PWT-143, PWT143, Pwt-143, Zandelisib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm Of Mature B-Cells (EFO_0000096), Diffuse Large B-Cell Lymphoma (EFO_0000403)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PIK3CD (ENSG00000171608)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.645 | Q17 | What gene does the drug Yttrium Y 90 Epratuzumab target? | The drug Yttrium Y 90 Epratuzumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD22. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%yttrium y 90 epratuzumab%" OR LOWER(tradeNames_string) LIKE "%yttrium y 90 epratuzumab%" OR LOWER(drugSynonyms_string) LIKE "%yttrium y 90 epratuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1182', 'drugName': 'Yttrium Y 90 Epratuzumab Tetraxetan', 'tradeNames_string': '', 'drugSynonyms_string': '(sup 90)y-dota-hll2, 2F35K89X9W, 90Y-DOTA-HLL2, 90y-epratuzumab, S9S0Y-DOTA-HLL2, Y-90-dota-hll2, Yttrium y 90 epratuzumab tetraxetan', 'linkedDiseasesDrug_string': 'Neoplasm Of Mature B-Cells (EFO_0000096), Diffuse Large B-Cell Lymphoma (EFO_0000403), Follicular Lymphoma (MONDO_0018906), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3402', 'drugName': 'Yttrium Y 90 Epratuzumab', 'tradeNames_string': 'Lymphocide', 'drugSynonyms_string': '90Y-HLL2, 90Y_HLL2, Epratuzumab (y 90), S9S0Y-HLL2, Yttrium y 90 epratuzumab, Yttrium y-90 epratuzumab', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD22 (ENSG00000012124)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.306 | Q17 | What gene does the drug Sintilimab target? | The drug Sintilimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene PDCD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%sintilimab%" OR LOWER(tradeNames_string) LIKE "%sintilimab%" OR LOWER(drugSynonyms_string) LIKE "%sintilimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4449', 'drugName': 'Sintilimab', 'tradeNames_string': 'Tyvyt', 'drugSynonyms_string': 'ANTI-PD-1 MONOCLONAL ANTIBODY IBI308, IBI-308, IBI308, Ibi308, Sintilimab', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neuroblastoma (EFO_0000621), Clear Cell Adenocarcinoma (EFO_0000348), Oral Cavity Cancer (EFO_0005570), Intrahepatic Cholangiocarcinoma (EFO_1001961), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Angiosarcoma (EFO_0003968), Gastric Cancer (MONDO_0001056), Neuroendocrine Carcinoma (MONDO_0002120), Esophageal Carcinoma (EFO_0002916), Cervical Adenocarcinoma (EFO_0001416), Ovarian Cancer (MONDO_0008170), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Colorectal Neoplasm (EFO_0004142), Gastric Adenocarcinoma (EFO_0000503), Lymphoma (EFO_0000574), Oral Squamous Cell Carcinoma (EFO_0000199), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Diffuse Large B-Cell Lymphoma (EFO_0000403), Biliary Tract Cancer (MONDO_0003060), Cholangiocarcinoma (EFO_0005221), Pancreatic Carcinoma (EFO_0002618), Neuroendocrine Neoplasm (EFO_1001901), Small Cell Lung Carcinoma (EFO_0000702), Undifferentiated Pleomorphic Sarcoma (EFO_1001972), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Mesothelioma (EFO_0000588), Clear Cell Renal Carcinoma (EFO_0000349), Soft Tissue Sarcoma (EFO_1001968), Renal Cell Carcinoma (EFO_0000681), Lung Neoplasm (MONDO_0021117), Salivary Gland Cancer (MONDO_0004669), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Carcinoma (EFO_0000313), Cutaneous T-Cell Lymphoma (EFO_0002913), Pancreatic Neoplasm (EFO_0003860), Hodgkins Lymphoma (EFO_0000183), Cervical Cancer (MONDO_0002974), Rectum Cancer (EFO_1000657), Squamous Cell Carcinoma (EFO_0000707), Neoplasm (EFO_0000616), Esophageal Squamous Cell Carcinoma (EFO_0005922), Lung Cancer (MONDO_0008903), Nasopharyngeal Neoplasm (EFO_0004252), Colorectal Adenocarcinoma (EFO_0000365), Non-Small Cell Lung Carcinoma (EFO_0003060), Classic Hodgkin Lymphoma (MONDO_0009348), Sarcoma (EFO_0000691), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDCD1 (ENSG00000188389)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.725 | Q17 | What gene does the drug Enoxaparin Sodium target? | The drug Enoxaparin Sodium targets the gene SERPINC1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enoxaparin sodium%" OR LOWER(tradeNames_string) LIKE "%enoxaparin sodium%" OR LOWER(drugSynonyms_string) LIKE "%enoxaparin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_282', 'drugName': 'Enoxaparin Sodium', 'tradeNames_string': 'Clexane, Enoxaparin sodium, Enoxaparin sodium (preservative free), Lovenox, Lovenox (preservative free)', 'drugSynonyms_string': 'Enoxaparin, Enoxaparin sodium, Enoxaparin sodium salt, Klexane, PK 10169, PK-10169, RP 54563, RP-54563', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Hip Fracture (EFO_0003964), Infection (EFO_0000544), Hemorrhage (MP_0001914), Covid-19 (MONDO_0100096), Obesity (EFO_0001073), Venous Thrombosis (HP_0004936), St Elevation Myocardial Infarction (EFO_0008585), Pulmonary Embolism (EFO_0003827), Esophageal Carcinoma (EFO_0002916), Ovarian Cancer (MONDO_0008170), Myocardial Ischemia (EFO_1001375), Nephrotic Syndrome (EFO_0004255), Recurrent Thrombophlebitis (HP_0004419), Atrial Fibrillation (EFO_0000275), Fetal Growth Restriction (EFO_0000495), Lymphoma (EFO_0000574), Female Reproductive System Neoplasm (MONDO_0021148), Acute Myocardial Infarction (EFO_0008583), Thrombotic Disease (MONDO_0000831), Acute Coronary Syndrome (EFO_0005672), Thromboembolism (HP_0001907), Pancreatic Carcinoma (EFO_0002618), Small Cell Lung Carcinoma (EFO_0000702), Stroke (EFO_0000712), Myocardial Infarction (EFO_0000612), Venous Thromboembolism (EFO_0004286), Habitual Abortion (EFO_1000954), Staphylococcus Aureus Infection (EFO_0005681), Neoplasm (EFO_0000616), Deep Vein Thrombosis (EFO_0003907), Non-Small Cell Lung Carcinoma (EFO_0003060), Blood Coagulation Disease (EFO_0009314), Kidney Disease (EFO_0003086), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SERPINC1 (ENSG00000117601)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.631 | Q17 | What gene does the drug Desoxycorticosterone Acetate target? | The drug Desoxycorticosterone Acetate targets the gene NR3C2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%desoxycorticosterone acetate%" OR LOWER(tradeNames_string) LIKE "%desoxycorticosterone acetate%" OR LOWER(drugSynonyms_string) LIKE "%desoxycorticosterone acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_184', 'drugName': 'Desoxycorticosterone Acetate', 'tradeNames_string': 'Doca, Percorten', 'drugSynonyms_string': '11-deoxycorticosterone, 11-deoxycorticosterone acetate, 21-hydroxyprogesterone, Deoxycorticosterone, Deoxycorticosterone acetate, Deoxycortone, Desoxycorticosterone, Desoxycorticosterone acetate, Desoxycortone, Desoxycortone acetate, NSC-11319, NSC-9567', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1939, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C2 (ENSG00000151623)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.8 | Q17 | What gene does the drug Humax-Il8 target? | The drug Humax-Il8 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CXCL8. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%humax-il8%" OR LOWER(tradeNames_string) LIKE "%humax-il8%" OR LOWER(drugSynonyms_string) LIKE "%humax-il8%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4247', 'drugName': 'Humax-Il8', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS-986253, BMS986253, Bms 986253, HUMAX-IL8, Humax-il-8, Humax-il8, Humax-inflam, MDX-018', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Hepatocellular Carcinoma (EFO_0000182), Neoplasm (EFO_0000616), Covid-19 (MONDO_0100096), Melanoma (EFO_0000756), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Myelodysplastic Syndrome (EFO_0000198), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CXCL8 (ENSG00000169429)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.810 | Q17 | What gene does the drug Viloxazine Hydrochloride target? | The drug Viloxazine Hydrochloride targets the gene SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%viloxazine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%viloxazine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%viloxazine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5502', 'drugName': 'Viloxazine Hydrochloride', 'tradeNames_string': 'Qelbree, Vivalan', 'drugSynonyms_string': 'ICI 58,834, ICI-58834, SPN-812, Spn-812, Viloxazine hcl, Viloxazine hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1058 | Q17 | What gene does the drug Oncolysin B target? | The drug Oncolysin B is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD19. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oncolysin b%" OR LOWER(tradeNames_string) LIKE "%oncolysin b%" OR LOWER(drugSynonyms_string) LIKE "%oncolysin b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3992', 'drugName': 'Oncolysin B', 'tradeNames_string': '', 'drugSynonyms_string': 'ONCOLYSIN B', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD19 (ENSG00000177455)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.340 | Q17 | What gene does the drug Ask-8007 target? | The drug Ask-8007 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SPP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ask-8007%" OR LOWER(tradeNames_string) LIKE "%ask-8007%" OR LOWER(drugSynonyms_string) LIKE "%ask-8007%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4873', 'drugName': 'Ask-8007', 'tradeNames_string': '', 'drugSynonyms_string': 'ASK-8007, Ask-8007', 'linkedDiseasesDrug_string': 'Rheumatoid Arthritis (EFO_0000685)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SPP1 (ENSG00000118785)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.48 | Q17 | What gene does the drug Oxycodone Terephthalate target? | The drug Oxycodone Terephthalate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxycodone terephthalate%" OR LOWER(tradeNames_string) LIKE "%oxycodone terephthalate%" OR LOWER(drugSynonyms_string) LIKE "%oxycodone terephthalate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_754', 'drugName': 'Oxycodone Terephthalate', 'tradeNames_string': '', 'drugSynonyms_string': 'Oxycodone terephthalate', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1950, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1481 | Q17 | What gene does the drug Ponesimod target? | The drug Ponesimod targets the gene S1PR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ponesimod%" OR LOWER(tradeNames_string) LIKE "%ponesimod%" OR LOWER(drugSynonyms_string) LIKE "%ponesimod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3600', 'drugName': 'Ponesimod', 'tradeNames_string': 'Ponvory', 'drugSynonyms_string': 'ACT-128800, Ponesimod', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Psoriasis (EFO_0000676), Immune System Disease (EFO_0000540)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.109 | Q17 | What gene does the drug Anifrolumab target? | The drug Anifrolumab targets the gene IFNAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anifrolumab%" OR LOWER(tradeNames_string) LIKE "%anifrolumab%" OR LOWER(drugSynonyms_string) LIKE "%anifrolumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4280', 'drugName': 'Anifrolumab', 'tradeNames_string': 'Saphnelo', 'drugSynonyms_string': 'Anifrolumab, Anifrolumab fnia, Anifrolumab-fnia, MEDI-546', 'linkedDiseasesDrug_string': 'Immune System Disease (EFO_0000540), Sjogren Syndrome (EFO_0000699), Systemic Lupus Erythematosus (MONDO_0007915), Rheumatoid Arthritis (EFO_0000685), Lupus Nephritis (EFO_0005761), Scleroderma (EFO_1001993)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.353 | Q17 | What gene does the drug Norethindrone target? | The drug Norethindrone targets the gene PGR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%norethindrone%" OR LOWER(tradeNames_string) LIKE "%norethindrone%" OR LOWER(drugSynonyms_string) LIKE "%norethindrone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3759', 'drugName': 'Norethindrone', 'tradeNames_string': 'Aygestin, Camila, Errin, Heather, Incassia, Jencycla, Menzol, Micronor, Micronor hrt, Nor-qd, Norethidrone, Norethindrone, Noriday, Norlutin, Primolut n, Utovlan', 'drugSynonyms_string': 'Activella, Anovule, Aygestin, Calluna vulgaris, Calluna vulgaris whole, Combipatch, Femhrt, Gestest, Heather whole, NSC-9564, Norethindrone, Norethisteron, Norethisterone, Norethisteronum, Norlutate, SC-4640, Triella', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Ischemia Reperfusion Injury (EFO_0002687), Neoplasm (EFO_0000616), Secondary Progressive Multiple Sclerosis (EFO_0008522), Menopause (EFO_0003922), Pain (EFO_0003843), Dysmenorrhea (HP_0100607), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Endometriosis (EFO_0001065), Hyperandrogenism (EFO_0009006), Sexual Dysfunction (EFO_0004714), Primary Progressive Multiple Sclerosis (EFO_0008520), Hepatitis C Virus Infection (EFO_0003047)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2855', 'drugName': 'Norethindrone Acetate', 'tradeNames_string': 'Aygestin, Norethidrone Acetate, Norethindrone acetate, Norlutate', 'drugSynonyms_string': 'NSC-22844, Norethindrone acetate, Norethisteron acetate, Norethisterone 17-acetate, Norethisterone acetate, Norethisteroni acetas, Norethynyltestosterone, Norlutin acetate, SH-420', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Breast Cancer (MONDO_0007254), Hemorrhage (MP_0001914), Pain (EFO_0003843), Premature Ovarian Insufficiency (HP_0008209), Uterine Fibroid (EFO_0000731), Lymphoma (EFO_0000574), Endometriosis (EFO_0001065), Cystic Fibrosis (MONDO_0009061), Acne (EFO_0003894), Pregnancy (EFO_0002950)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PGR (ENSG00000082175)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.241 | Q17 | What gene does the drug Spirapril Hydrochloride target? | The drug Spirapril Hydrochloride targets the gene ACE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%spirapril hydrochloride%" OR LOWER(tradeNames_string) LIKE "%spirapril hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%spirapril hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4466', 'drugName': 'Spirapril Hydrochloride', 'tradeNames_string': 'Renormax', 'drugSynonyms_string': 'SCH 33844, SCH-33844, Spirapril hcl, Spirapril hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACE (ENSG00000159640)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.216 | Q17 | What gene does the drug Ebdarokimab target? | The drug Ebdarokimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 3 genes: IL12A, IL12B and IL23A | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ebdarokimab%" OR LOWER(tradeNames_string) LIKE "%ebdarokimab%" OR LOWER(drugSynonyms_string) LIKE "%ebdarokimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_344', 'drugName': 'Ebdarokimab', 'tradeNames_string': '', 'drugSynonyms_string': 'AK-101, AK101, Ak101, Ebdarokimab', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_345', 'drugName': 'Ebdarokimab', 'tradeNames_string': '', 'drugSynonyms_string': 'AK-101, AK101, Ak101, Ebdarokimab', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL12B (ENSG00000113302), IL12A (ENSG00000168811), IL23A (ENSG00000110944)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1827 | Q17 | What gene does the drug Pamidronate Disodium target? | The drug Pamidronate Disodium targets the gene FDPS. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pamidronate disodium%" OR LOWER(tradeNames_string) LIKE "%pamidronate disodium%" OR LOWER(drugSynonyms_string) LIKE "%pamidronate disodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4184', 'drugName': 'Pamidronate Disodium', 'tradeNames_string': 'Aredia, Pamidronate disodium', 'drugSynonyms_string': 'CGP 23339AE, CGP-23339AE, Disodium pamidronate, Pamidronate disodium, Pamidronate disodium hydrate, Pamidronate disodium pentahydrate', 'linkedDiseasesDrug_string': 'Sapho Syndrome (EFO_1001164), Multiple Myeloma (EFO_0001378), Osteogenesis Imperfecta (MONDO_0019019), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 1991, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FDPS (ENSG00000160752)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1138 | Q17 | What gene does the drug Amphetamine Aspartate target? | The drug Amphetamine Aspartate targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amphetamine aspartate%" OR LOWER(tradeNames_string) LIKE "%amphetamine aspartate%" OR LOWER(drugSynonyms_string) LIKE "%amphetamine aspartate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1231', 'drugName': 'Amphetamine Aspartate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amfetamine aspartate, Amphetamine aspartate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1232', 'drugName': 'Amphetamine Aspartate', 'tradeNames_string': '', 'drugSynonyms_string': 'Amfetamine aspartate, Amphetamine aspartate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.800 | Q17 | What gene does the drug Ibuprofen Lysine target? | The drug Ibuprofen Lysine targets 2 genes: PTGS2 and PTGS1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ibuprofen lysine%" OR LOWER(tradeNames_string) LIKE "%ibuprofen lysine%" OR LOWER(drugSynonyms_string) LIKE "%ibuprofen lysine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4050', 'drugName': 'Ibuprofen Lysine', 'tradeNames_string': 'Feminax express, Ibuprofen lysine, Neoprofen, Nurofen advance, Nurofen max strgth mig pain, Nurofen migraine pain, Nurofen tension headache', 'drugSynonyms_string': 'Arfen, Dolormin, Ibuprofen l-lysine, Ibuprofen lysinate, Ibuprofen lysine, Imbun, Lisiprofen, Saren, Solufenum, Soluphene', 'linkedDiseasesDrug_string': 'Patent Ductus Arteriosus (HP_0001643)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGS2 (ENSG00000073756), PTGS1 (ENSG00000095303)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1123 | Q17 | What gene does the drug Phenytoin target? | The drug Phenytoin targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%phenytoin%" OR LOWER(tradeNames_string) LIKE "%phenytoin%" OR LOWER(drugSynonyms_string) LIKE "%phenytoin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1082', 'drugName': 'Phenytoin Sodium', 'tradeNames_string': 'Dilantin, Diphenylan sodium, Extended phenytoin sodium, Pentran, Phenytek, Phenytex, Phenytoin sodium, Prompt phenytoin sodium', 'drugSynonyms_string': '5,5-diphenylhydantoin sodium salt, Antisacer, Diphenylhydantoin sodium, NSC-757274, Phenytoin Sodium, Phenytoin sodium, Phenytoin sodium extended, Phenytoin sodium for injection, Phenytoin sodium salt, Phenytoin sodium, extended, Phenytoin sodium, prompt, Phenytoin sodium,extended, Phenytoin sodium,prompt, Phenytoinum natricum, Tacosal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3767', 'drugName': 'Phenytoin', 'tradeNames_string': 'Dilabid, Dilantin, Dilantin-125, Dilantin-30, Diphenylhydantoin, Hydantol, Phentytoin, Phenytoin', 'drugSynonyms_string': 'Diphenylhydantoin, Epamin, Lepitoin, NSC-8722, Phenytek, Phenytex, Phenytoin, Phenytoinum, SM-88 COMPONENT PHENYTOIN, Zentropil', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Neuroblastoma (EFO_0000621), Optic Neuritis (EFO_0007405), Ewing Sarcoma (EFO_0000174), Thalassemia (EFO_1001996), Leukemia (EFO_0000565), Anemia (Phenotype) (EFO_0004272), Seizure (HP_0001250), Sickle Cell Anemia (MONDO_0011382), Dementia (HP_0000726), Polyneuropathy (EFO_0009562), Anxiety (EFO_0005230), Lymphoma (EFO_0000574), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Depressive Disorder (MONDO_0002050), Injury (EFO_0000546), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_993', 'drugName': 'Fosphenytoin', 'tradeNames_string': '', 'drugSynonyms_string': 'Fosphenytoin, Np-06', 'linkedDiseasesDrug_string': 'Status Epilepticus (EFO_0008526), Epilepsy (EFO_0000474), Seizure (HP_0001250)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_181', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_string': 'Cerebyx, Fosphenytoin sodium, Pro-epanutin, Sesquient', 'drugSynonyms_string': 'ACC-9653-010, ACC-9653-010 (SODIUM SALT), CI 982, CI-982, Fosphenytoin disodium salt, Fosphenytoin sodium', 'linkedDiseasesDrug_string': 'Seizure (HP_0001250)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_5011', 'drugName': 'Mephenytoin', 'tradeNames_string': 'Mesantoin', 'drugSynonyms_string': 'Mephenytoin, Methoin, NSC-34652', 'linkedDiseasesDrug_string': 'Epilepsy (EFO_0000474)', 'yearOfFirstApproval': 1946, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1583 | Q17 | What gene does the drug Oxymetholone target? | The drug Oxymetholone targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxymetholone%" OR LOWER(tradeNames_string) LIKE "%oxymetholone%" OR LOWER(drugSynonyms_string) LIKE "%oxymetholone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_111', 'drugName': 'Oxymetholone', 'tradeNames_string': 'Anadrol, Anadrol-50, Anapolon 50', 'drugSynonyms_string': 'Anadrol, Anapolon, Anasteron, CI-406, HMD, NSC-26,198, NSC-26198, Oximetholone, Oxymetholone, Oxymetholone ciii, Pardroyd', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1672 | Q17 | What gene does the drug Menotropins target? | The drug Menotropins targets 2 genes: LHCGR and FSHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%menotropins%" OR LOWER(tradeNames_string) LIKE "%menotropins%" OR LOWER(drugSynonyms_string) LIKE "%menotropins%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1661', 'drugName': 'Lh (Menotropins)', 'tradeNames_string': '', 'drugSynonyms_string': 'Human lh, Lh (menotropins)', 'linkedDiseasesDrug_string': 'Infertility (EFO_0000545)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_206', 'drugName': 'Follitropin Alfa', 'tradeNames_string': 'Bemfola, Follistim, Follistim aq, Gonal-f, Gonal-f rff, Gonal-f rff redi-ject, Ovaleap, Puregon', 'drugSynonyms_string': 'Follitropin alfa, Follitropin alfa/beta, Follitropin beta, Fsh (menotropins), Human FSH', 'linkedDiseasesDrug_string': 'Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Anovulation (MONDO_0002775), Infertility (EFO_0000545)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'FSHR (ENSG00000170820)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1765', 'drugName': 'Menotropins', 'tradeNames_string': 'Humegon, Menopur, Merional, Normegon, Pergonal, Pergonal low lh', 'drugSynonyms_string': 'FSH, Follicle stimulating hormone, Follotropin, HMG, Human follicle stimulating hormone, Menotrophin, Menotropins, Menotropins (fsh;lh)', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Kallmann Syndrome (MONDO_0018800), Infertility (EFO_0000545), Azoospermia (EFO_0000279), Pregnancy (EFO_0002950), Gonadal Disorder (MONDO_0002259)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039), FSHR (ENSG00000170820)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1764', 'drugName': 'Menotropins', 'tradeNames_string': 'Humegon, Menopur, Merional, Normegon, Pergonal, Pergonal low lh', 'drugSynonyms_string': 'FSH, Follicle stimulating hormone, Follotropin, HMG, Human follicle stimulating hormone, Menotrophin, Menotropins, Menotropins (fsh;lh)', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Female Infertility (EFO_0008560), Kallmann Syndrome (MONDO_0018800), Infertility (EFO_0000545), Azoospermia (EFO_0000279), Pregnancy (EFO_0002950), Gonadal Disorder (MONDO_0002259)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'LHCGR (ENSG00000138039), FSHR (ENSG00000170820)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.529 | Q17 | What gene does the drug Zimeldine target? | The drug Zimeldine targets 17 genes: HTR1F, HTR1D, HTR3D, HTR3C, HTR5A, HTR2A, HTR2B, HTR3E, HTR1B, HTR1E, HTR1A, HTR3B, HTR2C, HTR7, HTR4, HTR3A and HTR6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zimeldine%" OR LOWER(tradeNames_string) LIKE "%zimeldine%" OR LOWER(drugSynonyms_string) LIKE "%zimeldine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_893', 'drugName': 'Zimeldine', 'tradeNames_string': '', 'drugSynonyms_string': 'Cis-zimelidine, Normud, Zelmid, Zimeldine, Zimelidine', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 17}, {'UUID': 'DrugGeneTargets_v2_6383', 'drugName': 'Zimeldine Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'H 102/09 HYDROCHLORIDE, Zimeldine hcl, Zimeldine hydrochloride, Zimelidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1F (ENSG00000179097), HTR2B (ENSG00000135914), HTR4 (ENSG00000164270), HTR1B (ENSG00000135312), HTR3A (ENSG00000166736), HTR1A (ENSG00000178394), HTR1D (ENSG00000179546), HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), HTR1E (ENSG00000168830), HTR7 (ENSG00000148680), HTR6 (ENSG00000158748), HTR5A (ENSG00000157219), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 17}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.235 | Q17 | What gene does the drug Ensifentrine target? | The drug Ensifentrine is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: PDE4D, PDE3B, PDE3A, PDE4B, PDE4A and PDE4C | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ensifentrine%" OR LOWER(tradeNames_string) LIKE "%ensifentrine%" OR LOWER(drugSynonyms_string) LIKE "%ensifentrine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4823', 'drugName': 'Ensifentrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ensifentrine, Ls-193,855, Ls-193855, RPL-554, RPL554', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341), Asthma (MONDO_0004979), Covid-19 (MONDO_0100096), Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_4824', 'drugName': 'Ensifentrine', 'tradeNames_string': '', 'drugSynonyms_string': 'Ensifentrine, Ls-193,855, Ls-193855, RPL-554, RPL554', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341), Asthma (MONDO_0004979), Covid-19 (MONDO_0100096), Cystic Fibrosis (MONDO_0009061)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'PDE4A (ENSG00000065989), PDE4D (ENSG00000113448), PDE4B (ENSG00000184588), PDE4C (ENSG00000105650), PDE3A (ENSG00000172572), PDE3B (ENSG00000152270)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.651 | Q17 | What gene does the drug Efepoetin Alfa target? | The drug Efepoetin Alfa is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EPOR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%efepoetin alfa%" OR LOWER(tradeNames_string) LIKE "%efepoetin alfa%" OR LOWER(drugSynonyms_string) LIKE "%efepoetin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_423', 'drugName': 'Efepoetin Alfa', 'tradeNames_string': '', 'drugSynonyms_string': 'Efepoetin alfa', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EPOR (ENSG00000187266)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1509 | Q17 | What gene does the drug Alflutinib target? | The drug Alflutinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alflutinib%" OR LOWER(tradeNames_string) LIKE "%alflutinib%" OR LOWER(drugSynonyms_string) LIKE "%alflutinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1492', 'drugName': 'Alflutinib', 'tradeNames_string': '', 'drugSynonyms_string': 'AST-2818, AST2818, Alflutinib, Furmonertinib', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Adenocarcinoma (EFO_0000571), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.539 | Q17 | What gene does the drug Levonordefrin target? | The drug Levonordefrin targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levonordefrin%" OR LOWER(tradeNames_string) LIKE "%levonordefrin%" OR LOWER(drugSynonyms_string) LIKE "%levonordefrin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4563', 'drugName': 'Levonordefrin', 'tradeNames_string': 'Neo-cobefrin', 'drugSynonyms_string': '(-)-cobefrin, BA 2818, BA-2818, Corbadrine, L-.alpha.-methylnoradrenaline, L-nordefrin, L-norephedrine, 3,4-dihydroxy-, Levonordefrin, NSC-757084, Neo-Cobefrin, Nordefrin, Nordefrin (-)-form, Nordefrin, l-', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1960, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1753 | Q17 | What gene does the drug Azd2066 target? | The drug Azd2066 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GRM5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azd2066%" OR LOWER(tradeNames_string) LIKE "%azd2066%" OR LOWER(drugSynonyms_string) LIKE "%azd2066%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2800', 'drugName': 'Azd2066', 'tradeNames_string': '', 'drugSynonyms_string': 'Azd 2066, Azd-2066, Azd2066', 'linkedDiseasesDrug_string': 'Diabetic Neuropathy (EFO_1000783), Pain (EFO_0003843), Chronic Pain (HP_0012532), Neuropathic Pain (EFO_0005762), Major Depressive Disorder (MONDO_0002009), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRM5 (ENSG00000168959)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.610 | Q17 | What gene does the drug Karenitecin target? | The drug Karenitecin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TOP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%karenitecin%" OR LOWER(tradeNames_string) LIKE "%karenitecin%" OR LOWER(drugSynonyms_string) LIKE "%karenitecin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_773', 'drugName': 'Karenitecin', 'tradeNames_string': '', 'drugSynonyms_string': 'Karenitecin', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Lung Cancer (MONDO_0008903), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Brain Neoplasm (EFO_0003833), Ovarian Cancer (MONDO_0008170)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TOP1 (ENSG00000198900)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1780 | Q17 | What gene does the drug Rg3487 target? | The drug Rg3487 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 6 genes: HTR3D, HTR3C, HTR3E, HTR3B, HTR3A and CHRNA7 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rg3487%" OR LOWER(tradeNames_string) LIKE "%rg3487%" OR LOWER(drugSynonyms_string) LIKE "%rg3487%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2120', 'drugName': 'Rg3487', 'tradeNames_string': '', 'drugSynonyms_string': 'Facinicline hydrochloride, MEM 3454, MEM-3454, MEM3454, RG-3487, RG3487, Rg3487', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_2119', 'drugName': 'Rg3487', 'tradeNames_string': '', 'drugSynonyms_string': 'Facinicline hydrochloride, MEM 3454, MEM-3454, MEM3454, RG-3487, RG3487, Rg3487', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_4325', 'drugName': 'Rg3487', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_4324', 'drugName': 'Rg3487', 'tradeNames_string': '', 'drugSynonyms_string': '', 'linkedDiseasesDrug_string': 'Schizophrenia (MONDO_0005090), Alzheimer Disease (MONDO_0004975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNA7 (ENSG00000175344), HTR3A (ENSG00000166736), HTR3E (ENSG00000186038), HTR3B (ENSG00000149305), HTR3D (ENSG00000186090), HTR3C (ENSG00000178084)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1083 | Q17 | What gene does the drug Ixazomib target? | The drug Ixazomib targets 38 genes: PSMD6, PSMC5, PSMB11, PSMA4, PSMC6, PSMC2, PSMB2, PSMA6, PSMA2, PSMD13, PSMB9, ADRM1, PSMD2, PSMB8, PSMB4, PSMD11, SEM1, PSMB10, PSMD14, PSMA3, PSMB1, PSMD4, PSMB3, PSMA5, PSMD12, PSMB6, PSMD7, PSMB5, PSMD8, PSMD1, PSMC4, PSMA1, PSMA8, PSMC3, PSMC1, PSMA7, PSMD3 and PSMB7. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ixazomib%" OR LOWER(tradeNames_string) LIKE "%ixazomib%" OR LOWER(drugSynonyms_string) LIKE "%ixazomib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3334', 'drugName': 'Ixazomib', 'tradeNames_string': 'Ninlaro', 'drugSynonyms_string': 'Ixazomib, MLN-2238, MLN-9708 FREE BASE, MLN2238', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Al Amyloidosis (MONDO_0019438), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Plasmacytoma (EFO_0006738), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Anemia, Hemolytic, Autoimmune (EFO_1001264), Triple-Negative Breast Cancer (EFO_0005537), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Waldenstrom Macroglobulinemia (EFO_0009441), Chronic Kidney Disease (EFO_0003884), Follicular Lymphoma (MONDO_0018906), Hiv Infection (EFO_0000764), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Lupus Nephritis (EFO_0005761)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'numberLinkedTargets': 38}, {'UUID': 'DrugGeneTargets_v2_4407', 'drugName': 'Ixazomib Citrate', 'tradeNames_string': 'Ninlaro', 'drugSynonyms_string': 'Ixazomib citrate, MLN-9708, MLN9708', 'linkedDiseasesDrug_string': "Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Mantle Cell Lymphoma (EFO_1001469), Al Amyloidosis (MONDO_0019438), Neoplasm (EFO_0000616), Kaposi'S Sarcoma (EFO_0000558), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Plasmacytoma (EFO_0006738), Lymphoblastic Lymphoma (MONDO_0000873), Acute Myeloid Leukemia (EFO_0000222), Waldenstrom Macroglobulinemia (EFO_0009441), Glioblastoma Multiforme (EFO_0000519), Plasma Cell Leukemia (EFO_0006475)", 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PSMD1 (ENSG00000173692), PSMB2 (ENSG00000126067), PSMB1 (ENSG00000008018), PSMB5 (ENSG00000100804), PSMB8 (ENSG00000204264), PSMB9 (ENSG00000240065), PSMB6 (ENSG00000142507), PSMD14 (ENSG00000115233), PSMA1 (ENSG00000129084), PSMA2 (ENSG00000106588), PSMA3 (ENSG00000100567), PSMA4 (ENSG00000041357), PSMA5 (ENSG00000143106), PSMA6 (ENSG00000100902), PSMA7 (ENSG00000101182), PSMA8 (ENSG00000154611), PSMB10 (ENSG00000205220), PSMB11 (ENSG00000222028), PSMB3 (ENSG00000277791), PSMB4 (ENSG00000159377), PSMB7 (ENSG00000136930), ADRM1 (ENSG00000130706), PSMC2 (ENSG00000161057), PSMC1 (ENSG00000100764), PSMC4 (ENSG00000013275), PSMC6 (ENSG00000100519), PSMC3 (ENSG00000165916), PSMC5 (ENSG00000087191), PSMD2 (ENSG00000175166), PSMD3 (ENSG00000108344), PSMD12 (ENSG00000197170), PSMD11 (ENSG00000108671), PSMD6 (ENSG00000163636), PSMD7 (ENSG00000103035), PSMD13 (ENSG00000185627), PSMD4 (ENSG00000159352), PSMD8 (ENSG00000099341), SEM1 (ENSG00000127922)', 'numberLinkedTargets': 38}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1407 | Q17 | What gene does the drug Flurazepam target? | The drug Flurazepam targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flurazepam%" OR LOWER(tradeNames_string) LIKE "%flurazepam%" OR LOWER(drugSynonyms_string) LIKE "%flurazepam%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6336', 'drugName': 'Flurazepam', 'tradeNames_string': '', 'drugSynonyms_string': 'Dalmane, Flurazepam, Insumin', 'linkedDiseasesDrug_string': 'Dementia (HP_0000726), Anxiety (EFO_0005230), Depressive Disorder (MONDO_0002050), Insomnia (EFO_0004698), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_653', 'drugName': 'Flurazepam Hydrochloride', 'tradeNames_string': 'Dalmane, Flurazepam hydrochloride', 'drugSynonyms_string': 'Flurazepam, Flurazepam dihydrochloride, Flurazepam hydrochloride, Flurazepam hydrochloride civ, NSC-78559, RO 5-6901, RO-5-6901', 'linkedDiseasesDrug_string': 'Insomnia (EFO_0004698)', 'yearOfFirstApproval': 1970, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.62 | Q17 | What gene does the drug Demecarium target? | The drug Demecarium targets the gene ACHE. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%demecarium%" OR LOWER(tradeNames_string) LIKE "%demecarium%" OR LOWER(drugSynonyms_string) LIKE "%demecarium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2522', 'drugName': 'Demecarium', 'tradeNames_string': '', 'drugSynonyms_string': 'Demecarium, Demecarium cation, Demecarium ion', 'linkedDiseasesDrug_string': 'Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4088', 'drugName': 'Demecarium Bromide', 'tradeNames_string': 'Humorsol, Tosmilen', 'drugSynonyms_string': 'BC-48, Demecarium bromide, Demekastigmine bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ACHE (ENSG00000087085)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1643 | Q17 | What gene does the drug Loxapine target? | The drug Loxapine targets 5 genes: DRD4, HTR2A, DRD2, HTR2C and DRD3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loxapine%" OR LOWER(tradeNames_string) LIKE "%loxapine%" OR LOWER(drugSynonyms_string) LIKE "%loxapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_490', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5990', 'drugName': 'Loxapine Hydrochloride', 'tradeNames_string': 'Loxitane c, Loxitane im', 'drugSynonyms_string': 'Loxapine hcl, Loxapine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5989', 'drugName': 'Loxapine Hydrochloride', 'tradeNames_string': 'Loxitane c, Loxitane im', 'drugSynonyms_string': 'Loxapine hcl, Loxapine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_488', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4041', 'drugName': 'Loxapine', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugSynonyms_string': 'CL 62,362, CL-62362, Loxapac, Loxapine, Loxitane, SUM 3170, SUM-3170', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4042', 'drugName': 'Loxapine', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugSynonyms_string': 'CL 62,362, CL-62362, Loxapac, Loxapine, Loxitane, SUM 3170, SUM-3170', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5988', 'drugName': 'Loxapine Hydrochloride', 'tradeNames_string': 'Loxitane c, Loxitane im', 'drugSynonyms_string': 'Loxapine hcl, Loxapine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_489', 'drugName': 'Loxapine Succinate', 'tradeNames_string': 'Loxapac, Loxapine, Loxapine succinate, Loxitane', 'drugSynonyms_string': 'CL 71563, CL-71563, Loxapine succinate, NSC-759578', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2A (ENSG00000102468), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4043', 'drugName': 'Loxapine', 'tradeNames_string': 'Adasuve, Loxitane intramuscular [as hydrochloride], Loxitane-c oral suspension [as hydrochloride]', 'drugSynonyms_string': 'CL 62,362, CL-62362, Loxapac, Loxapine, Loxitane, SUM 3170, SUM-3170', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Asthma (MONDO_0004979), Bipolar I Disorder (EFO_0009963), Nicotine Dependence (EFO_0003768), Agitation (HP_0000713), Delirium (EFO_0009267), Migraine Disorder (MONDO_0005277), Chronic Obstructive Pulmonary Disease (EFO_0000341), Neuropathic Pain (EFO_0005762), Anxiety (EFO_0005230), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), HTR2C (ENSG00000147246), DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.95 | Q17 | What gene does the drug Suramin target? | The drug Suramin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene FGF1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%suramin%" OR LOWER(tradeNames_string) LIKE "%suramin%" OR LOWER(drugSynonyms_string) LIKE "%suramin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3192', 'drugName': 'Suramin', 'tradeNames_string': '', 'drugSynonyms_string': 'FARMA-939, Farma, Fourneau, Metaret, NSC-34936, Naganol, Suramin, Suramine', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Multiple Myeloma (EFO_0001378), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Leishmaniasis (EFO_0005044), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Hand, Foot And Mouth Disease (EFO_0007294), Renal Cell Carcinoma (EFO_0000681), Acute Kidney Injury (HP_0001919), Colorectal Carcinoma (EFO_1001951), Autism Spectrum Disorder (EFO_0003756), Prostate Adenocarcinoma (EFO_0000673), Trypanosomiasis (DOID_10113)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGF1 (ENSG00000113578)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3528', 'drugName': 'Suramin Hexasodium', 'tradeNames_string': '', 'drugSynonyms_string': 'BAY-205, BAYER-205, CI-1003, FOURNEAU 309, FOURNEAU-309, NF-060, NSC-758165, Nagananinum, Naphuride, Suramin hexasodium, Suramin sodium, Suraminum natricum', 'linkedDiseasesDrug_string': 'Central Nervous System Neoplasm (EFO_1000158), Multiple Myeloma (EFO_0001378), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Leishmaniasis (EFO_0005044), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Adrenal Cortex Carcinoma (EFO_1000796), Hand, Foot And Mouth Disease (EFO_0007294), Renal Cell Carcinoma (EFO_0000681), Acute Kidney Injury (HP_0001919), Colorectal Carcinoma (EFO_1001951), Autism Spectrum Disorder (EFO_0003756), Prostate Adenocarcinoma (EFO_0000673), Trypanosomiasis (DOID_10113)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FGF1 (ENSG00000113578)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.673 | Q17 | What gene does the drug Azathioprine Sodium target? | The drug Azathioprine Sodium targets the gene PPAT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%azathioprine sodium%" OR LOWER(tradeNames_string) LIKE "%azathioprine sodium%" OR LOWER(drugSynonyms_string) LIKE "%azathioprine sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4861', 'drugName': 'Azathioprine Sodium', 'tradeNames_string': 'Azathioprine sodium, Imuran', 'drugSynonyms_string': 'Azathioprine sodium, Azathioprine sodium salt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PPAT (ENSG00000128059)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.284 | Q17 | What gene does the drug Albuterol target? | The drug Albuterol targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%albuterol%" OR LOWER(tradeNames_string) LIKE "%albuterol%" OR LOWER(drugSynonyms_string) LIKE "%albuterol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2058', 'drugName': 'Levalbuterol Tartrate', 'tradeNames_string': 'Xopenex, Xopenex hfa', 'drugSynonyms_string': 'Levalbuterol tartrate, Levosalbutamol tartrate', 'linkedDiseasesDrug_string': 'Bronchospasm (HP_0025428), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1434', 'drugName': 'Albuterol', 'tradeNames_string': 'Aerolin, Aerolin 400, Aerolin auto, Airomir, Airsalb, Albuterol, Asmasal clickhaler, Asmasal spacehaler, Asmaven, Asmavent, Cobutolin, Combivent, Combivent udvs, Ipramol steri-neb, Kentamol, Libetist, Maxivent, Proair Hfa, Proventil, Proventil Hfa, Rimasal, Salamol e-breathe, Salapin, Salbulin novolizer, Salbuvent, Salipraneb, Steri-neb salamol, Ventmax sr, Ventodisks, Ventolin, Ventolin Hfa, Ventolin cr, Ventolin e-breathe, Volmax', 'drugSynonyms_string': 'Accuneb, Albuterol, Combivent, Duoneb, Etinoline, NSC-757417, PROVENTIL-HFA, SCH 13949W, SCH-13949W, Salbutamol, Salbutamolum, Ventoline, Volmax', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Status Asthmaticus (EFO_0008590), Pulmonary Hypertension (MONDO_0005149), Cough (HP_0012735), Pulmonary Arterial Hypertension (EFO_0001361), Idiopathic Pulmonary Fibrosis (EFO_0000768), Lung Disease (EFO_0003818), Spinal Cord Injury (EFO_1001919), Bronchiolitis (HP_0011950), Idiopathic Pulmonary Arterial Hypertension (MONDO_0017147), Bronchospasm (HP_0025428), Congestive Heart Failure (EFO_0000373), Lymphangioleiomyomatosis (MONDO_0011705), Seasonal Allergic Rhinitis (EFO_0003956), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Pulmonary Edema (EFO_1001134), Organophosphate Poisoning (EFO_0010581), Familial Dysautonomia (Orphanet_1764), Asthma (MONDO_0004979), Memory Impairment (EFO_0001072), Tachypnea (EFO_0009840), Chronic Obstructive Pulmonary Disease (EFO_0000341), Primary Ciliary Dyskinesia (MONDO_0016575), Airway Obstruction (HP_0006536), Glycogen Storage Disease Due To Acid Maltase Deficiency (Orphanet_365), Allergic Disease (MONDO_0005271), Congenital Myasthenic Syndromes (Orphanet_590), Respiratory Failure (EFO_0009686), Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 1981, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6278', 'drugName': 'Albuterol Sulfate', 'tradeNames_string': 'Accuneb, Albuterol sulfate, Proair, Proair digihaler, Proair hfa, Proair respiclick, Proventil, Proventil-hfa, Ventolin, Ventolin hfa, Ventolin rotacaps, Volmax, Vospire er', 'drugSynonyms_string': 'Albuterol sulfate, Albuterol sulphate, Buventol, Ecovent, Hexotonal, Loftan, NSC-289928, R03AC02, R03CC02, SCH 13949W SULFATE, SCH-13949W SULFATE, Salamol, Salbumol, Salbutamol (as sulfate), Salbutamol sulfate, Salbutamol sulphate, Salbutamoli sulfas, Sch 13949w sulphate, Sch-13949w sulphate, Sulbutamol (as sulphate), Sultanol, Torpex, Venetlin, Ventilastin, Vospire', 'linkedDiseasesDrug_string': 'Status Asthmaticus (EFO_0008590), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Chronic Obstructive Pulmonary Disease (EFO_0000341), Cardiovascular Disease (EFO_0000319), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Lung Disease (EFO_0003818)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1198', 'drugName': 'Levalbuterol Hydrochloride', 'tradeNames_string': 'Levalbuterol hydrochloride, Xopenex', 'drugSynonyms_string': 'Albuterol (r)-form hydrochloride, Albuterol hydrochloride, r-, Levalbuterol hcl, Levalbuterol hydrochloride, Levosalbutamol hydrochloride, NSC-759255', 'linkedDiseasesDrug_string': 'Asthma (MONDO_0004979)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3721', 'drugName': 'Levosalbutamol', 'tradeNames_string': '', 'drugSynonyms_string': 'ASF-1096, Albuterol (r)-form, Levalbuterol, Levosalbutamol, R-salbutamol, Xopenex', 'linkedDiseasesDrug_string': 'Chronic Obstructive Pulmonary Disease (EFO_0000341), Bronchospasm (HP_0025428), Asthma (MONDO_0004979)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1796 | Q17 | What gene does the drug Daxibotulinumtoxina target? | The drug Daxibotulinumtoxina targets the gene SNAP25. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%daxibotulinumtoxina%" OR LOWER(tradeNames_string) LIKE "%daxibotulinumtoxina%" OR LOWER(drugSynonyms_string) LIKE "%daxibotulinumtoxina%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4481', 'drugName': 'Daxibotulinumtoxina', 'tradeNames_string': 'Daxxify', 'drugSynonyms_string': 'Daxibotulinumtoxina, Daxibotulinumtoxina-lanm, RTI-150, RTI150, RTT150', 'linkedDiseasesDrug_string': 'Skin Aging (EFO_0005422), Torticollis (HP_0000473)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SNAP25 (ENSG00000132639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.364 | Q17 | What gene does the drug Methscopolamine target? | The drug Methscopolamine targets 2 genes: CHRM3 and CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methscopolamine%" OR LOWER(tradeNames_string) LIKE "%methscopolamine%" OR LOWER(drugSynonyms_string) LIKE "%methscopolamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2032', 'drugName': 'Methscopolamine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-n-methylscopolamine, Methscopolamine cation, Methscopolamine ion, Methylscopolamine, N-methylhyoscine, N-methylscopolamine', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2031', 'drugName': 'Methscopolamine', 'tradeNames_string': '', 'drugSynonyms_string': '(-)-n-methylscopolamine, Methscopolamine cation, Methscopolamine ion, Methylscopolamine, N-methylhyoscine, N-methylscopolamine', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2696', 'drugName': 'Methscopolamine Bromide', 'tradeNames_string': 'Methscopolamine bromide, Pamine, Pamine forte', 'drugSynonyms_string': '(-)-Scopolamine Methyl Bromide, Epoxytropine tropate methylbromide, Holopon, Hyoscine methobromide, Methscopolamine bromide, Methylscopolamine bromide, N-methylscopolamine bromide, N-methylscopolamine methylsulfate, NSC-120606, Scopolamine methyl bromide, Scopolamine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2695', 'drugName': 'Methscopolamine Bromide', 'tradeNames_string': 'Methscopolamine bromide, Pamine, Pamine forte', 'drugSynonyms_string': '(-)-Scopolamine Methyl Bromide, Epoxytropine tropate methylbromide, Holopon, Hyoscine methobromide, Methscopolamine bromide, Methylscopolamine bromide, N-methylscopolamine bromide, N-methylscopolamine methylsulfate, NSC-120606, Scopolamine methyl bromide, Scopolamine methylbromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1953, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1468 | Q17 | What gene does the drug Romidepsin target? | The drug Romidepsin targets 11 genes: HDAC4, HDAC3, HDAC2, HDAC1, HDAC5, HDAC7, HDAC8, HDAC9, HDAC11, HDAC6 and HDAC10. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%romidepsin%" OR LOWER(tradeNames_string) LIKE "%romidepsin%" OR LOWER(drugSynonyms_string) LIKE "%romidepsin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6063', 'drugName': 'Romidepsin', 'tradeNames_string': 'Chromadax, Istodax', 'drugSynonyms_string': 'Depsipeptide, FK-228, FK228, FR-901228, FR901228, NSC-630176, Romidepsin', 'linkedDiseasesDrug_string': "Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Papillary Thyroid Carcinoma (EFO_0000641), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Anaplastic Large Cell Lymphoma (EFO_0003032), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Colorectal Carcinoma (EFO_1001951), Ovarian Cancer (MONDO_0008170), Acute Promyelocytic Leukemia (EFO_0000224), Anaplastic Astrocytoma (EFO_0002499), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Gastric Adenocarcinoma (EFO_0000503), Male Breast Carcinoma (EFO_0006861), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Liposarcoma (EFO_0000569), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Urethra Cancer (MONDO_0004192), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Anaplastic Oligodendroglioma (EFO_0002501), Small Cell Lung Carcinoma (EFO_0000702), Triple-Negative Breast Cancer (EFO_0005537), Hiv-1 Infection (EFO_0000180), Cutaneous T-Cell Lymphoma (EFO_0002913), Hodgkins Lymphoma (EFO_0000183), Mature T-Cell And Nk-Cell Non-Hodgkin Lymphoma (MONDO_0000430), Follicular Lymphoma (MONDO_0018906), Hiv Infection (EFO_0000764), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Non-Small Cell Lung Carcinoma (EFO_0003060), Melanoma (EFO_0000756), Follicular Thyroid Carcinoma (EFO_0000501), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)", 'yearOfFirstApproval': 2009, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HDAC1 (ENSG00000116478), HDAC3 (ENSG00000171720), HDAC6 (ENSG00000094631), HDAC2 (ENSG00000196591), HDAC5 (ENSG00000108840), HDAC7 (ENSG00000061273), HDAC8 (ENSG00000147099), HDAC11 (ENSG00000163517), HDAC4 (ENSG00000068024), HDAC9 (ENSG00000048052), HDAC10 (ENSG00000100429)', 'numberLinkedTargets': 11}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1169 | Q17 | What gene does the drug Bavisant target? | The drug Bavisant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HRH3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bavisant%" OR LOWER(tradeNames_string) LIKE "%bavisant%" OR LOWER(drugSynonyms_string) LIKE "%bavisant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_188', 'drugName': 'Bavisant', 'tradeNames_string': '', 'drugSynonyms_string': 'Bavisant, JNJ-31001074', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.854 | Q17 | What gene does the drug Isocarboxazid target? | The drug Isocarboxazid targets 2 genes: MAOB and MAOA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%isocarboxazid%" OR LOWER(tradeNames_string) LIKE "%isocarboxazid%" OR LOWER(drugSynonyms_string) LIKE "%isocarboxazid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1881', 'drugName': 'Isocarboxazid', 'tradeNames_string': 'Marplan', 'drugSynonyms_string': 'Enerzer, Isocarboxazid, NSC-169893, RO 5-0831, RO-5-0831', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Unipolar Depression (EFO_0003761), Major Depressive Disorder (MONDO_0002009)', 'yearOfFirstApproval': 1959, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOA (ENSG00000189221), MAOB (ENSG00000069535)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1379 | Q17 | What gene does the drug Inolimomab target? | The drug Inolimomab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IL2RA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%inolimomab%" OR LOWER(tradeNames_string) LIKE "%inolimomab%" OR LOWER(drugSynonyms_string) LIKE "%inolimomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4321', 'drugName': 'Inolimomab', 'tradeNames_string': 'Leucotac', 'drugSynonyms_string': 'BT-563, Inolimomab, Leukotac', 'linkedDiseasesDrug_string': 'Graft Versus Host Disease (MONDO_0013730)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IL2RA (ENSG00000134460)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.113 | Q17 | What gene does the drug Gonadorelin Acetate target? | The drug Gonadorelin Acetate targets the gene GNRHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%gonadorelin acetate%" OR LOWER(tradeNames_string) LIKE "%gonadorelin acetate%" OR LOWER(drugSynonyms_string) LIKE "%gonadorelin acetate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3355', 'drugName': 'Gonadorelin Acetate', 'tradeNames_string': 'Cystorelin, Factrel, GnRH, Gonadotropin Releasing Hormone, Lh Releasing Factor, Lutrelef, Lutrepulse, Lutrepulse kit', 'drugSynonyms_string': 'ABBOTT-41070, Fertagyl, Gonadorelin acetate, Gonadorelin acetate anhydrous, Gonadorelin acetate mixture, Gonadorelin diacetate, Hypocrine, Luteinizing, Luteinizing hormone-releasing factor diacetate tetrahydrate', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Kallmann Syndrome (MONDO_0018800), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Metastatic Prostate Cancer (EFO_0000196), Infertility (EFO_0000545), Hypogonadotropic Hypogonadism (MONDO_0018555), Prostate Carcinoma (EFO_0001663), Prostate Adenocarcinoma (EFO_0000673)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GNRHR (ENSG00000109163)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.43 | Q17 | What gene does the drug Nandrolone Decanoate target? | The drug Nandrolone Decanoate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nandrolone decanoate%" OR LOWER(tradeNames_string) LIKE "%nandrolone decanoate%" OR LOWER(drugSynonyms_string) LIKE "%nandrolone decanoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5812', 'drugName': 'Nandrolone Decanoate', 'tradeNames_string': 'Deca-durabolin, Durabolin, Nandrolone decanoate', 'drugSynonyms_string': 'Nandrolone decanoate, Nandrolone decanoate ciii', 'linkedDiseasesDrug_string': 'Malnutrition (EFO_0008572), Eye Disease (EFO_0003966), Hip Fracture (EFO_0003964), Hiv Wasting Syndrome (EFO_0007312)', 'yearOfFirstApproval': 1983, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.128 | Q17 | What gene does the drug Methadone Hydrochloride target? | The drug Methadone Hydrochloride targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methadone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%methadone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%methadone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6241', 'drugName': 'Methadone Hydrochloride', 'tradeNames_string': 'Dolophine hydrochloride, Eptadone, Martindale, Methadone hydrochloride, Methadone hydrochloride intensol, Methadose, Metharose, Methex, Physeptone, Pinadone, Synastone, Westadone', 'drugSynonyms_string': 'AN-148, Butalgin, Dolofin hydrochloride, Dolophine, Fenadone, Heptadon, Ketalgin hydrochloride, Mecodin, Methadone hcl, Methadone hydrochloride, Methadone hydrochloride cii, Methadonium chloride, NSC-19600, Phenadone hydrochloride', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Hiv Infection (EFO_0000764), Intervertebral Disc Degeneration (HP_0008419), Pain (EFO_0003843), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1947, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.207 | Q17 | What gene does the drug Methoxamine target? | The drug Methoxamine targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methoxamine%" OR LOWER(tradeNames_string) LIKE "%methoxamine%" OR LOWER(drugSynonyms_string) LIKE "%methoxamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_34', 'drugName': 'Methoxamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Methoxamine, NRL-001, NRL001, Nrl001, Vasoxyl', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Urinary Incontinence (HP_0000020), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_1111', 'drugName': 'Methoxamine Hydrochloride', 'tradeNames_string': 'Vasoxine, Vasoxyl', 'drugSynonyms_string': 'Methoxamine hcl, Methoxamine hydrochloride, NSC-757102', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523)', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.53 | Q17 | What gene does the drug Bivalirudin target? | The drug Bivalirudin targets the gene F2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bivalirudin%" OR LOWER(tradeNames_string) LIKE "%bivalirudin%" OR LOWER(drugSynonyms_string) LIKE "%bivalirudin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4317', 'drugName': 'Bivalirudin', 'tradeNames_string': 'Angiomax, Angiomax rtu, Bivalirudin, Bivalirudin in 0.9% sodium chloride', 'drugSynonyms_string': 'BG-8967, BG8967, Bivalirudin', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Thrombocytopenia (HP_0001873), Heart Disease (EFO_0003777), Coronary Artery Disease (EFO_0001645), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Aortic Stenosis (EFO_0000266), Hemorrhage (MP_0001914), Deep Vein Thrombosis (EFO_0003907), Cardiovascular Disease (EFO_0000319), Myocardial Infarction (EFO_0000612), Subarachnoid Hemorrhage (EFO_0000713), Acute Myocardial Infarction (EFO_0008583), Acute Coronary Syndrome (EFO_0005672), Thrombotic Disease (MONDO_0000831), Intermediate Coronary Syndrome (EFO_1000985)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'F2 (ENSG00000180210)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.551 | Q17 | What gene does the drug Difelikefalin target? | The drug Difelikefalin targets the gene OPRK1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%difelikefalin%" OR LOWER(tradeNames_string) LIKE "%difelikefalin%" OR LOWER(drugSynonyms_string) LIKE "%difelikefalin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4408', 'drugName': 'Difelikefalin', 'tradeNames_string': 'Korsuva', 'drugSynonyms_string': '4-PIPERIDINECARBOXYLIC ACID, N1-(D-PHENYLALANYL-D-PHENYLALANYL-D-LEUCYL-D-LYSYL)-4-AMINO-, CR-845, CR845, Cr-845 acetate, Difelikefalin, Difelikefalin acetate, FE-202845, FE202845, MR-13A9, MR13A9', 'linkedDiseasesDrug_string': 'Chronic Kidney Disease (EFO_0003884), Pruritus (HP_0000989), Osteoarthritis (MONDO_0005178), Pain (EFO_0003843)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.71 | Q17 | What gene does the drug Rizatriptan target? | The drug Rizatriptan targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%rizatriptan%" OR LOWER(tradeNames_string) LIKE "%rizatriptan%" OR LOWER(drugSynonyms_string) LIKE "%rizatriptan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1141', 'drugName': 'Rizatriptan Benzoate', 'tradeNames_string': 'Maxalt, Maxalt-mlt, Rizatriptan benzoate', 'drugSynonyms_string': 'MK-0462, NSC-758919, Rizatriptan benzoate', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1140', 'drugName': 'Rizatriptan Benzoate', 'tradeNames_string': 'Maxalt, Maxalt-mlt, Rizatriptan benzoate', 'drugSynonyms_string': 'MK-0462, NSC-758919, Rizatriptan benzoate', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4539', 'drugName': 'Rizatriptan', 'tradeNames_string': 'Maxalt', 'drugSynonyms_string': 'L-705126, MK-462, MK-462 FREE BASE, Maxalt, Maxalt-Mlt, Rizatriptan', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4538', 'drugName': 'Rizatriptan', 'tradeNames_string': 'Maxalt', 'drugSynonyms_string': 'L-705126, MK-462, MK-462 FREE BASE, Maxalt, Maxalt-Mlt, Rizatriptan', 'linkedDiseasesDrug_string': 'Migraine With Aura (MONDO_0005475), Migraine Disorder (MONDO_0005277), Migraine Without Aura (MONDO_0100431)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1D (ENSG00000179546), HTR1B (ENSG00000135312)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1816 | Q17 | What gene does the drug Protriptyline target? | The drug Protriptyline targets 2 genes: SLC6A4 and SLC6A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%protriptyline%" OR LOWER(tradeNames_string) LIKE "%protriptyline%" OR LOWER(drugSynonyms_string) LIKE "%protriptyline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6366', 'drugName': 'Protriptyline', 'tradeNames_string': '', 'drugSynonyms_string': 'Protriptyline', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6365', 'drugName': 'Protriptyline', 'tradeNames_string': '', 'drugSynonyms_string': 'Protriptyline', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5493', 'drugName': 'Protriptyline Hydrochloride', 'tradeNames_string': 'Concordin-10, Concordin-5, Protriptyline hydrochloride, Vivactil', 'drugSynonyms_string': 'MK-240, NSC-169912, Protriptyline hcl, Protriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5492', 'drugName': 'Protriptyline Hydrochloride', 'tradeNames_string': 'Concordin-10, Concordin-5, Protriptyline hydrochloride, Vivactil', 'drugSynonyms_string': 'MK-240, NSC-169912, Protriptyline hcl, Protriptyline hydrochloride', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A4 (ENSG00000108576)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1745 | Q17 | What gene does the drug Fluvastatin Sodium target? | The drug Fluvastatin Sodium targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fluvastatin sodium%" OR LOWER(tradeNames_string) LIKE "%fluvastatin sodium%" OR LOWER(drugSynonyms_string) LIKE "%fluvastatin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1184', 'drugName': 'Fluvastatin Sodium', 'tradeNames_string': 'Dorisin xl, Fluvastatin sodium, Lescol, Lescol xl, Luvinsta xl, Nandovar xl, Pinmactil, Stefluvin xl', 'drugSynonyms_string': 'Almastatin, Canef, Cranoc, Fluindostatin, Fluvastatin sodium, Fluvastatin sodium salt, Fractal, Lipaxan, Lochol, Locol, Primexin, Vastin, XU 62-320, XU-62-320', 'linkedDiseasesDrug_string': 'Familial Hypercholesterolemia (EFO_0004911), Breast Cancer (MONDO_0007254), Hypercholesterolemia (HP_0003124)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.186 | Q17 | What gene does the drug Metformin target? | The drug Metformin targets 51 genes: NDUFA13, GPD2, NDUFA6, NDUFA8, NDUFB6, NDUFAF4, NDUFA12, NDUFV3, NDUFA9, NDUFB4, NDUFS7, NDUFC1, NDUFS6, NDUFS5, MT-ND1, NDUFA11, NDUFB7, NDUFAF1, NDUFA4, MT-ND5, NDUFB2, NDUFA3, MT-ND2, NDUFB10, NDUFS8, MT-ND4L, NDUFV2, NDUFB8, NDUFC2, NDUFS4, NDUFB1, NDUFS2, MT-ND6, NDUFS1, NDUFA5, NDUFA10, NDUFAF3, NDUFA1, NDUFB3, NDUFS3, NDUFB9, NDUFB5, NDUFB11, NDUFA7, NDUFAB1, NDUFA4L2, NDUFV1, NDUFAF2, MT-ND3, MT-ND4 and NDUFA2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%metformin%" OR LOWER(tradeNames_string) LIKE "%metformin%" OR LOWER(drugSynonyms_string) LIKE "%metformin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1886', 'drugName': 'Metformin', 'tradeNames_string': '', 'drugSynonyms_string': 'LA-6023, Metformin, Metformin extended release', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ovarian Carcinoma (EFO_0001075), Migraine Disorder (MONDO_0005277), Lung Carcinoma (EFO_0001071), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Polycystic Ovary Syndrome (EFO_0000660), Fragile X Syndrome (MONDO_0010383), Hypertension (EFO_0000537), Huntington Disease (MONDO_0007739), Neuropathic Pain (EFO_0005762), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Sickle Cell Anemia (MONDO_0011382), Hypercholesterolemia (HP_0003124), Generalized Anxiety Disorder (EFO_1001892), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Neoplasm Of Thorax (MONDO_0021350), Follicular Lymphoma (MONDO_0018906), Intermittent Vascular Claudication (EFO_0003876), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Colorectal Adenocarcinoma (EFO_0000365), Burn (EFO_0009516), Body Weight Gain (EFO_0004566), Prediabetes Syndrome (EFO_1001121), Glioblastoma Multiforme (EFO_0000519), Diabetes Insipidus (MONDO_0004782), Schizophrenia (MONDO_0005090), Barrett'S Esophagus (EFO_0000280), Atherosclerosis (EFO_0003914), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Pancreatic Neuroendocrine Tumor (EFO_1000045), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Abdominal Aortic Aneurysm (EFO_0004214), Bardet-Biedl Syndrome (MONDO_0015229), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Li-Fraumeni Syndrome (MONDO_0018875), Breast Carcinoma In Situ (MONDO_0004658), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Metabolic Disease (EFO_0000589), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Diabetic Retinopathy (EFO_0003770), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Non-Alcoholic Steatohepatitis (EFO_1001249), Acute Lymphoblastic Leukemia (EFO_0000220), Diffuse Large B-Cell Lymphoma (EFO_0000403), Secondary Progressive Multiple Sclerosis (EFO_0008522), Bronchoalveolar Adenocarcinoma (EFO_0000308), Insulin Resistance (EFO_0002614), Small Cell Lung Carcinoma (EFO_0000702), Elevated Hepatic Transaminase (HP_0002910), Abnormal Glucose Tolerance (EFO_0002546), Duchenne Muscular Dystrophy (MONDO_0010679), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Large Cell Lung Carcinoma (EFO_0003050), Obstructive Sleep Apnea (EFO_0003918), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Frontotemporal Dementia (MONDO_0017276), Esophageal Squamous Cell Carcinoma (EFO_0005922), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Metabolic Syndrome (EFO_0000195), Low Back Pain (HP_0003419), Blindness (Disorder) (MONDO_0001941), Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Peripheral Neuropathy (EFO_0003100), Peripheral Arterial Disease (EFO_0004265), Pulmonary Arterial Hypertension (EFO_0001361), Glaucoma (MONDO_0005041), Intellectual Disability (HP_0001249), Leprosy (EFO_0001054), Primary Progressive Multiple Sclerosis (EFO_0008520), Ovarian Cancer (MONDO_0008170), Atrial Fibrillation (EFO_0000275), Breast Cancer (MONDO_0007254), Neurobehavioral Manifestations (EFO_0004364), Cardiovascular Disease (EFO_0000319), Acute Coronary Syndrome (EFO_0005672), Diabetic Foot (EFO_1001459), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Periodontitis (EFO_0000649), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pleural Effusion (EFO_0009637), Atrophic Macular Degeneration (EFO_1001492), Mental Deterioration (HP_0001268), Pancreatic Carcinoma (EFO_0002618), Infertility (EFO_0000545), Chronic Obstructive Pulmonary Disease (EFO_0000341), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Stargardt Disease (MONDO_0019353), Hepatic Steatosis (HP_0001397), Systolic Heart Failure (EFO_1001207), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Spastic Cerebral Palsy (MONDO_0000396), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Heart Failure (EFO_0003144), Hepatitis (HP_0012115), Metastatic Prostate Cancer (EFO_0000196), Neoplasm (EFO_0000616), Tuberculosis (MONDO_0018076), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Muscular Dystrophy (MONDO_0020121), Endometrial Cancer (MONDO_0011962), Ulcerative Colitis (EFO_0000729), Malaria (EFO_0001068), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Schizoaffective Disorder (EFO_0005411), Oral Squamous Cell Carcinoma (EFO_0000199), Disorder Of Lipid Metabolism (Orphanet_309005), Endometrial Carcinoma (EFO_1001512), Inflammation (MP_0001845), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Cognitive Impairment (HP_0100543), Squamous Cell Carcinoma (EFO_0000707), Melanoma (EFO_0000756), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), Sex Chromosome Disorder Of Sex Development (MONDO_0017975)", 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'numberLinkedTargets': 51}, {'UUID': 'DrugGeneTargets_v2_1885', 'drugName': 'Metformin', 'tradeNames_string': '', 'drugSynonyms_string': 'LA-6023, Metformin, Metformin extended release', 'linkedDiseasesDrug_string': "Familial Adenomatous Polyposis (Orphanet_733), Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Ovarian Carcinoma (EFO_0001075), Migraine Disorder (MONDO_0005277), Lung Carcinoma (EFO_0001071), Pregnancy (EFO_0002950), Malignant Colon Neoplasm (MONDO_0021063), Cervical Adenocarcinoma (EFO_0001416), Polycystic Ovary Syndrome (EFO_0000660), Fragile X Syndrome (MONDO_0010383), Hypertension (EFO_0000537), Huntington Disease (MONDO_0007739), Neuropathic Pain (EFO_0005762), Non-Alcoholic Fatty Liver Disease (EFO_0003095), Neuroendocrine Neoplasm (EFO_1001901), Lung Adenocarcinoma (EFO_0000571), Sickle Cell Anemia (MONDO_0011382), Hypercholesterolemia (HP_0003124), Generalized Anxiety Disorder (EFO_1001892), Brain Neoplasm (EFO_0003833), Carcinoma (EFO_0000313), Breast Ductal Carcinoma In Situ (EFO_0000432), Liver Cancer (MONDO_0002691), Cervical Cancer (MONDO_0002974), Neoplasm Of Thorax (MONDO_0021350), Follicular Lymphoma (MONDO_0018906), Intermittent Vascular Claudication (EFO_0003876), Lung Cancer (MONDO_0008903), Diabetic Neuropathy (EFO_1000783), Colorectal Adenocarcinoma (EFO_0000365), Burn (EFO_0009516), Body Weight Gain (EFO_0004566), Prediabetes Syndrome (EFO_1001121), Glioblastoma Multiforme (EFO_0000519), Diabetes Insipidus (MONDO_0004782), Schizophrenia (MONDO_0005090), Barrett'S Esophagus (EFO_0000280), Atherosclerosis (EFO_0003914), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Pancreatic Neuroendocrine Tumor (EFO_1000045), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Obesity (EFO_0001073), Abdominal Aortic Aneurysm (EFO_0004214), Bardet-Biedl Syndrome (MONDO_0015229), Aging (GO_0007568), Colorectal Carcinoma (EFO_1001951), Li-Fraumeni Syndrome (MONDO_0018875), Breast Carcinoma In Situ (MONDO_0004658), Angiosarcoma (EFO_0003968), Prostate Carcinoma (EFO_0001663), Metabolic Disease (EFO_0000589), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Diabetic Retinopathy (EFO_0003770), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Non-Alcoholic Steatohepatitis (EFO_1001249), Acute Lymphoblastic Leukemia (EFO_0000220), Diffuse Large B-Cell Lymphoma (EFO_0000403), Secondary Progressive Multiple Sclerosis (EFO_0008522), Bronchoalveolar Adenocarcinoma (EFO_0000308), Insulin Resistance (EFO_0002614), Small Cell Lung Carcinoma (EFO_0000702), Elevated Hepatic Transaminase (HP_0002910), Abnormal Glucose Tolerance (EFO_0002546), Duchenne Muscular Dystrophy (MONDO_0010679), Triple-Negative Breast Cancer (EFO_0005537), Thyroid Cancer (MONDO_0002108), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Large Cell Lung Carcinoma (EFO_0003050), Obstructive Sleep Apnea (EFO_0003918), Rectum Cancer (EFO_1000657), Chronic Kidney Disease (EFO_0003884), Urogenital Neoplasm (EFO_0003863), Osteoarthritis (MONDO_0005178), Frontotemporal Dementia (MONDO_0017276), Esophageal Squamous Cell Carcinoma (EFO_0005922), Hiv Infection (EFO_0000764), Non-Small Cell Lung Carcinoma (EFO_0003060), Hiv-Associated Lipodystrophy Syndrome (EFO_1001348), Metabolic Syndrome (EFO_0000195), Low Back Pain (HP_0003419), Blindness (Disorder) (MONDO_0001941), Diabetes Mellitus (EFO_0000400), Coronary Artery Disease (EFO_0001645), Peripheral Neuropathy (EFO_0003100), Peripheral Arterial Disease (EFO_0004265), Pulmonary Arterial Hypertension (EFO_0001361), Glaucoma (MONDO_0005041), Intellectual Disability (HP_0001249), Leprosy (EFO_0001054), Primary Progressive Multiple Sclerosis (EFO_0008520), Ovarian Cancer (MONDO_0008170), Atrial Fibrillation (EFO_0000275), Breast Cancer (MONDO_0007254), Neurobehavioral Manifestations (EFO_0004364), Cardiovascular Disease (EFO_0000319), Acute Coronary Syndrome (EFO_0005672), Diabetic Foot (EFO_1001459), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Periodontitis (EFO_0000649), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pleural Effusion (EFO_0009637), Atrophic Macular Degeneration (EFO_1001492), Mental Deterioration (HP_0001268), Pancreatic Carcinoma (EFO_0002618), Infertility (EFO_0000545), Chronic Obstructive Pulmonary Disease (EFO_0000341), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Stargardt Disease (MONDO_0019353), Hepatic Steatosis (HP_0001397), Systolic Heart Failure (EFO_1001207), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Spastic Cerebral Palsy (MONDO_0000396), Adenocarcinoma (EFO_0000228), Urinary Bladder Cancer (MONDO_0001187), Heart Failure (EFO_0003144), Hepatitis (HP_0012115), Metastatic Prostate Cancer (EFO_0000196), Neoplasm (EFO_0000616), Tuberculosis (MONDO_0018076), Major Depressive Disorder (MONDO_0002009), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Muscular Dystrophy (MONDO_0020121), Endometrial Cancer (MONDO_0011962), Ulcerative Colitis (EFO_0000729), Malaria (EFO_0001068), Prostate Adenocarcinoma (EFO_0000673), Breast Carcinoma (EFO_0000305), Ascites (HP_0001541), Prostate Cancer (MONDO_0008315), Colorectal Neoplasm (EFO_0004142), Schizoaffective Disorder (EFO_0005411), Oral Squamous Cell Carcinoma (EFO_0000199), Disorder Of Lipid Metabolism (Orphanet_309005), Endometrial Carcinoma (EFO_1001512), Inflammation (MP_0001845), Bipolar Disorder (MONDO_0004985), Rheumatoid Arthritis (EFO_0000685), Endometrioid Carcinoma (EFO_0000466), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Cognitive Impairment (HP_0100543), Squamous Cell Carcinoma (EFO_0000707), Melanoma (EFO_0000756), Hidradenitis Suppurativa (EFO_1000710), Severe Acute Respiratory Syndrome (EFO_0000694), Sex Chromosome Disorder Of Sex Development (MONDO_0017975)", 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'numberLinkedTargets': 51}, {'UUID': 'DrugGeneTargets_v2_1888', 'drugName': 'Metformin Hydrochloride', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugSynonyms_string': 'Apophage, Benofomin, Diabefagos, Diabex, EX-404, EX404, Glucaminol, LA-6023, Metformin hcl, Metformin hydrochloride, NSC-91485, Neodipa, Siamformet, Walaphage', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'numberLinkedTargets': 51}, {'UUID': 'DrugGeneTargets_v2_1887', 'drugName': 'Metformin Hydrochloride', 'tradeNames_string': 'Bolamyn sr, Diagemet xl, Fortamet, Glucamet 500, Glucamet 850, Glucient sr, Glucophage, Glucophage sr, Glucophage xr, Glumetza, Glyformin, Janumet, Ledermetin, Metabet sr, Metformin hydrochloride, Metsol, Milform, Orabet, Riomet, Riomet er, Sukkarto sr', 'drugSynonyms_string': 'Apophage, Benofomin, Diabefagos, Diabex, EX-404, EX404, Glucaminol, LA-6023, Metformin hcl, Metformin hydrochloride, NSC-91485, Neodipa, Siamformet, Walaphage', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Multiple Myeloma (EFO_0001378), Fanconi Anemia (MONDO_0019391), Obesity (EFO_0001073), Lung Carcinoma (EFO_0001071), Prostate Carcinoma (EFO_0001663), Malignant Colon Neoplasm (MONDO_0021063), Prostate Adenocarcinoma (EFO_0000673), Ascites (HP_0001541), Gliosarcoma (EFO_1001465), Polycystic Ovary Syndrome (EFO_0000660), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Diabetic Foot (EFO_1001459), Oral Squamous Cell Carcinoma (EFO_0000199), Pleural Effusion (EFO_0009637), Endometrial Carcinoma (EFO_1001512), Pancreatic Carcinoma (EFO_0002618), Lung Adenocarcinoma (EFO_0000571), Gestational Diabetes (EFO_0004593), Peritoneum Cancer (MONDO_0002087), Hyperinsulinemia (HP_0000842), Inflammation (MP_0001845), Stargardt Disease (MONDO_0019353), Breast Ductal Carcinoma In Situ (EFO_0000432), Endometrioid Carcinoma (EFO_0000466), Chronic Kidney Disease (EFO_0003884), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Diabetic Neuropathy (EFO_1000783), Ovarian Serous Cystadenocarcinoma (EFO_1000043), Heart Failure (EFO_0003144), Non-Small Cell Lung Carcinoma (EFO_0003060), Metabolic Syndrome (EFO_0000195), Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GPD2 (ENSG00000115159), MT-ND6 (ENSG00000198695), NDUFA10 (ENSG00000130414), NDUFS8 (ENSG00000110717), MT-ND4L (ENSG00000212907), NDUFA6 (ENSG00000184983), MT-ND1 (ENSG00000198888), NDUFB6 (ENSG00000165264), NDUFA4 (ENSG00000189043), NDUFA11 (ENSG00000174886), NDUFB7 (ENSG00000099795), MT-ND2 (ENSG00000198763), NDUFS2 (ENSG00000158864), MT-ND5 (ENSG00000198786), NDUFA8 (ENSG00000119421), NDUFB5 (ENSG00000136521), MT-ND4 (ENSG00000198886), MT-ND3 (ENSG00000198840), NDUFAB1 (ENSG00000004779), NDUFA1 (ENSG00000125356), NDUFS4 (ENSG00000164258), NDUFB3 (ENSG00000119013), NDUFC1 (ENSG00000109390), NDUFA2 (ENSG00000131495), NDUFS5 (ENSG00000168653), NDUFS7 (ENSG00000115286), NDUFS6 (ENSG00000145494), NDUFB1 (ENSG00000183648), NDUFS3 (ENSG00000213619), NDUFA3 (ENSG00000170906), NDUFB4 (ENSG00000065518), NDUFB8 (ENSG00000166136), NDUFB2 (ENSG00000090266), NDUFA7 (ENSG00000267855), NDUFC2 (ENSG00000151366), NDUFB10 (ENSG00000140990), NDUFV2 (ENSG00000178127), NDUFS1 (ENSG00000023228), NDUFV1 (ENSG00000167792), NDUFV3 (ENSG00000160194), NDUFA5 (ENSG00000128609), NDUFA9 (ENSG00000139180), NDUFAF2 (ENSG00000164182), NDUFAF3 (ENSG00000178057), NDUFA4L2 (ENSG00000185633), NDUFB11 (ENSG00000147123), NDUFAF4 (ENSG00000123545), NDUFA13 (ENSG00000186010), NDUFA12 (ENSG00000184752), NDUFAF1 (ENSG00000137806), NDUFB9 (ENSG00000147684)', 'numberLinkedTargets': 51}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.140 | Q17 | What gene does the drug Fezolinetant target? | The drug Fezolinetant is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TACR3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fezolinetant%" OR LOWER(tradeNames_string) LIKE "%fezolinetant%" OR LOWER(drugSynonyms_string) LIKE "%fezolinetant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3996', 'drugName': 'Fezolinetant', 'tradeNames_string': '', 'drugSynonyms_string': 'A-2693, A2693, AS-3472693-00, AS3472693-00, ES-256364, ESN-364, ESN364, Esn364, Fezolinetant', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Hot Flashes (HP_0031217)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TACR3 (ENSG00000169836)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.907 | Q17 | What gene does the drug Tominersen target? | The drug Tominersen is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tominersen%" OR LOWER(tradeNames_string) LIKE "%tominersen%" OR LOWER(drugSynonyms_string) LIKE "%tominersen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3493', 'drugName': 'Tominersen', 'tradeNames_string': '', 'drugSynonyms_string': 'ISIS-443139 FREE ACID, Ionis httrx, Isis 443139, RG-6042 FREE ACID, RG6042, RG6042 FREE ACID, Rg6042, Ro7234292, Tominersen', 'linkedDiseasesDrug_string': 'Huntington Disease (MONDO_0007739)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTT (ENSG00000197386)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.803 | Q17 | What gene does the drug Esomeprazole Strontium target? | The drug Esomeprazole Strontium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esomeprazole strontium%" OR LOWER(tradeNames_string) LIKE "%esomeprazole strontium%" OR LOWER(drugSynonyms_string) LIKE "%esomeprazole strontium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2645', 'drugName': 'Esomeprazole Strontium', 'tradeNames_string': 'Esomeprazole strontium', 'drugSynonyms_string': 'Esomeprazole strontium, FM-0F67, FM0F67, HIP-1601, Hip1601, S-omeprazole strontium hydrate', 'linkedDiseasesDrug_string': 'Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Gastroesophageal Reflux Disease (EFO_0003948), Zollinger-Ellison Syndrome (EFO_0007549)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.135 | Q17 | What gene does the drug Treprostinil target? | The drug Treprostinil targets the gene PTGIR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%treprostinil%" OR LOWER(tradeNames_string) LIKE "%treprostinil%" OR LOWER(drugSynonyms_string) LIKE "%treprostinil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1758', 'drugName': 'Treprostinil', 'tradeNames_string': 'Remodulin, Tyvaso, Tyvaso dpi', 'drugSynonyms_string': '15-AU-81, 15AU81, L-606, LRX -15, LRX-15, Rumodolin, Treprostinil, Tresprostinil, UT-15, Uniprost', 'linkedDiseasesDrug_string': 'Recurrent Thrombophlebitis (HP_0004419), Pulmonary Hypertension (MONDO_0005149), Primary Pulmonary Hypertension (MONDO_0001999), Ischemia Reperfusion Injury (EFO_0002687), Raynaud Disease (EFO_1001145), Chronic Obstructive Pulmonary Disease (EFO_0000341), Adult Acute Respiratory Distress Syndrome (MONDO_0100130), Persistent Fetal Circulation Syndrome (EFO_1001103), Peripheral Vascular Disease (EFO_0003875), Pulmonary Arterial Hypertension (EFO_0001361), Diabetic Foot (EFO_1001459), Type 1 Diabetes Mellitus (MONDO_0005147), Idiopathic Pulmonary Fibrosis (EFO_0000768), Systemic Scleroderma (EFO_0000717), Ischemia (EFO_0000556), Congenital Heart Disease (EFO_0005207)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2433', 'drugName': 'Treprostinil Diolamine', 'tradeNames_string': 'Orenitram, Ut-15c', 'drugSynonyms_string': 'Treprostinil diethanolamine, Treprostinil diolamin, Treprostinil diolamine, UT-15C', 'linkedDiseasesDrug_string': 'Systemic Scleroderma (EFO_0000717), Pulmonary Arterial Hypertension (EFO_0001361)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.83 | Q17 | What gene does the drug Acebutolol Hydrochloride target? | The drug Acebutolol Hydrochloride targets the gene ADRB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acebutolol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%acebutolol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%acebutolol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_604', 'drugName': 'Acebutolol Hydrochloride', 'tradeNames_string': 'Acebut hcl, Acebutolol hydrochloride, Sectral, Sectral 200, Sectral 400', 'drugSynonyms_string': 'Acebutolol hcl, Acebutolol hydrochloride, Acetanol, B 17803A, B-17803A, IL-17803A, M&B 17803A, M&B-17803A, NSC-757412, Neptal, Prent', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Hypertension (EFO_0000537)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1541 | Q17 | What gene does the drug Mycophenolate Mofetil target? | The drug Mycophenolate Mofetil targets 2 genes: IMPDH2 and IMPDH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mycophenolate mofetil%" OR LOWER(tradeNames_string) LIKE "%mycophenolate mofetil%" OR LOWER(drugSynonyms_string) LIKE "%mycophenolate mofetil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_290', 'drugName': 'Mycophenolate Mofetil', 'tradeNames_string': 'Arzip, Cellcept, Mycophenolate mofetil, Myfenax', 'drugSynonyms_string': 'Myclausen, Mycophenolate mofetil, Mycophenolic acid 2-(4-morpholinyl)ethyl ester, Mycophenylate mofetil, NSC-724229, NSC-758905, RS-61443', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Vasculitis (EFO_0006803), Iga Glomerulonephritis (EFO_0004194), Lymphoid Neoplasm (EFO_0001642), Diamond-Blackfan Anemia (MONDO_0015253), Pemphigus Vulgaris (EFO_0004719), Hypertension (EFO_0000537), Childhood Acute Lymphoblastic Leukemia (MONDO_0000870), Shwachman-Diamond Syndrome (MONDO_0009833), Aplastic Anemia (HP_0001915), Granulomatosis With Polyangiitis (EFO_0005297), Immunodeficiency (HP_0002721), Limited Scleroderma (EFO_1001017), Sickle Cell Anemia (MONDO_0011382), Severe Combined Immunodeficiency (MONDO_0015974), Wiskott-Aldrich Syndrome (MONDO_0010518), Hematopoietic And Lymphoid System Neoplasm (MONDO_0002334), Malt Lymphoma (EFO_0000191), Gout (EFO_0004274), Heart Disease (EFO_0003777), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Interstitial Cystitis (EFO_0008507), Takayasu Arteritis (EFO_1001857), Kidney Disease (EFO_0003086), Epidermolysis Bullosa (EFO_1000690), Glioblastoma Multiforme (EFO_0000519), Adult T-Cell Leukemia/Lymphoma (MONDO_0019471), Lupus Nephritis (EFO_0005761), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Fanconi Anemia (MONDO_0019391), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Sjogren Syndrome (EFO_0000699), Autoimmune Thrombocytopenic Purpura (EFO_0007160), Neuroepithelial Neoplasm (MONDO_0021193), Anaplastic Large Cell Lymphoma (EFO_0003032), Pure Red-Cell Aplasia (MONDO_0001705), Neuromyelitis Optica (EFO_0004256), Familial Lipoprotein Lipase Deficiency (MONDO_0009387), Myelodysplastic Syndrome (EFO_0000198), Autoimmune Disease (EFO_0005140), Uveitis (EFO_1001231), Gliosarcoma (EFO_1001465), Hepatocellular Carcinoma (EFO_0000182), Mantle Cell Lymphoma (EFO_1001469), Beta-Thalassemia (Orphanet_848), Myelofibrosis (MONDO_0044903), Acute Lymphoblastic Leukemia (EFO_0000220), Fish-Eye Disease (Orphanet_79292), Acute Myeloid Leukemia (EFO_0000222), Interstitial Lung Disease (EFO_0004244), Diffuse Large B-Cell Lymphoma (EFO_0000403), Small Cell Lung Carcinoma (EFO_0000702), Severe Aplastic Anemia (EFO_0006927), Cauda Equina Syndrome (EFO_0007196), Hodgkins Lymphoma (EFO_0000183), Chronic Kidney Disease (EFO_0003884), Hiv Infection (EFO_0000764), Diabetic Nephropathy (EFO_0000401), Myeloproliferative Disorder (EFO_0004251), Juvenile Neuronal Ceroid Lipofuscinosis (MONDO_0019262), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211), Neuroblastoma (EFO_0000621), Primary Myelofibrosis (EFO_0002430), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Langerhans Cell Histiocytosis (EFO_1000318), Mucous Membrane Pemphigoid (EFO_1000680), Drug-Induced Liver Injury (EFO_0004228), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Mast-Cell Leukemia (EFO_0007359), Focal Segmental Glomerulosclerosis (EFO_0004236), Diffuse Scleroderma (EFO_0000404), Hepatitis, Alcoholic (EFO_1001345), Cardiovascular Disease (EFO_0000319), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), B-Cell Prolymphocytic Leukemia (EFO_1000102), Microscopic Polyangiitis (EFO_1000784), Pancreatic Carcinoma (EFO_0002618), 22Q11.2 Deletion Syndrome (MONDO_0018923), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Pulmonary Sarcoidosis (DOID_13406), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Cutaneous Melanoma (EFO_0000389), Age-Related Macular Degeneration (EFO_0001365), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), T-Cell Prolymphocytic Leukemia (EFO_1000560), Cytomegalovirus Infection (EFO_0001062), Type 1 Diabetes Mellitus (MONDO_0005147), Anti-Neutrophil Antibody Associated Vasculitis (EFO_0004826), Graft Versus Host Disease (MONDO_0013730), Kidney Failure (EFO_1002048), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Myasthenia Gravis (EFO_0004991), Angioimmunoblastic T-Cell Lymphoma (EFO_0000255), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Hepatitis C Virus Infection (EFO_0003047), Nephrotic Syndrome (EFO_0004255), Henoch-Schoenlein Purpura (EFO_1000965), Crohn'S Disease (EFO_0000384), Bullous Pemphigoid (EFO_0007187), Chronic Myelomonocytic Leukemia (EFO_1001779), Acute Graft Vs. Host Disease (EFO_0004599), Membranous Glomerulonephritis (EFO_0004254), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Lymphoblastic Lymphoma (MONDO_0000873), Renal Cell Carcinoma (EFO_0000681), Rheumatoid Arthritis (EFO_0000685), Systemic Scleroderma (EFO_0000717), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kidney Cancer (MONDO_0002367)", 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348), IMPDH2 (ENSG00000178035)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1227', 'drugName': 'Mycophenolic Acid', 'tradeNames_string': 'Mycophenolic acid, Myfortic', 'drugSynonyms_string': '68618, Mycophenolate, Mycophenolate mofetil impurity, mycophenolic acid-, Mycophenolic acid, NSC-129185, RS-61443 [AS MOFETIL]', 'linkedDiseasesDrug_string': "Nephrotic Syndrome (EFO_0004255), Chronic Kidney Disease (EFO_0003884), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Systemic Scleroderma (EFO_0000717), Crohn'S Disease (EFO_0000384), Immune System Disease (EFO_0000540), Sjogren Syndrome (EFO_0000699), Intermediate Uveitis (EFO_1000986), Graft Versus Host Disease (MONDO_0013730), Kidney Disease (EFO_0003086), Kidney Failure (EFO_1002048), Dry Eye Syndrome (EFO_1000906), Systemic Lupus Erythematosus (MONDO_0007915), Acute Graft Vs. Host Disease (EFO_0004599), Acute Myeloid Leukemia (EFO_0000222), Type 1 Diabetes Mellitus (MONDO_0005147), Autoimmune Disease (EFO_0005140), Lupus Nephritis (EFO_0005761)", 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348), IMPDH2 (ENSG00000178035)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4489', 'drugName': 'Mycophenolate Mofetil Hydrochloride', 'tradeNames_string': 'Cellcept, Mycophenolate mofetil hydrochloride', 'drugSynonyms_string': 'Mycophenolate mofetil hcl, Mycophenolate mofetil hydrochloride, RS-61443-190', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IMPDH1 (ENSG00000106348), IMPDH2 (ENSG00000178035)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.547 | Q17 | What gene does the drug Etidocaine Hydrochloride target? | The drug Etidocaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%etidocaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%etidocaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%etidocaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1658', 'drugName': 'Etidocaine Hydrochloride', 'tradeNames_string': 'Duranest', 'drugSynonyms_string': 'Duranest hydrochloride, Etidocaine hcl, Etidocaine hydrochloride, W-19053', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1596 | Q17 | What gene does the drug Antazoline target? | The drug Antazoline targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%antazoline%" OR LOWER(tradeNames_string) LIKE "%antazoline%" OR LOWER(drugSynonyms_string) LIKE "%antazoline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3299', 'drugName': 'Antazoline', 'tradeNames_string': 'Antaz sulf, Vasocon-a', 'drugSynonyms_string': 'Antazoline, Atazoline, Vasocon-A', 'linkedDiseasesDrug_string': 'Pterygium (EFO_0000678), Inflammation (MP_0001845), Allergic Disease (MONDO_0005271), Nasal Congestion (HP_0001742)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4047', 'drugName': 'Antazoline Phosphate', 'tradeNames_string': '', 'drugSynonyms_string': 'Antazoline phosphate, NSC-755865', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.992 | Q17 | What gene does the drug Pefcalcitol target? | The drug Pefcalcitol is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene VDR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pefcalcitol%" OR LOWER(tradeNames_string) LIKE "%pefcalcitol%" OR LOWER(drugSynonyms_string) LIKE "%pefcalcitol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2290', 'drugName': 'Pefcalcitol', 'tradeNames_string': '', 'drugSynonyms_string': 'M-5181, M-518101, M5181, M518101, Pefcalcitol', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'VDR (ENSG00000111424)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.168 | Q17 | What gene does the drug Pentobarbital target? | The drug Pentobarbital targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentobarbital%" OR LOWER(tradeNames_string) LIKE "%pentobarbital%" OR LOWER(drugSynonyms_string) LIKE "%pentobarbital%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2327', 'drugName': 'Pentobarbital', 'tradeNames_string': 'Nembutal', 'drugSynonyms_string': 'Mebubarbital, Mebumal, NSC-28708, Pentobarbital, Pentobarbital calcium, Pentobarbital cii, Pentobarbitone', 'linkedDiseasesDrug_string': 'Heart Disease (EFO_0003777), Drug Dependence (EFO_0003890), Brain Injury (MONDO_0043510), Insomnia (EFO_0004698), Status Epilepticus (EFO_0008526)', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}, {'UUID': 'DrugGeneTargets_v2_757', 'drugName': 'Pentobarbital Sodium', 'tradeNames_string': 'Beuthanasia, Euthanase, Euthatal, Nembutal, Nembutal sodium, Pentobarbital sodium, Pentobarbitone Sodium, Sagatal, Sodium pentobarbital', 'drugSynonyms_string': 'Auropan, Barpental, Biosedan, Diabutal, Embutal, Entobar, Etaminal sodium, Ethaminal sodium, Euthanyl, Euthatal, Isobarb, Mebubarbital sodium, Mebumal sodium, NSC-10816, Napental, Narcoren, Pacifan, Pental, Pentobarbital sodium, Pentobarbital sodium salt, Pentobarbitone sodium, Pentonal, Pentone, Praecicalm, Rs-pentobarbital sodium, Sagatal, Sodium ethaminal, Sodium nembutal, Sodium pental, Sodium pentobarbitone, Sodium pentobarbiturate, Sodium-pent, Soluble pentobarbital, Somnopentyl, Somnotol, Sopental, Sotyl, V-pento, Vetbutal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.251 | Q17 | What gene does the drug Osilodrostat Phosphate target? | The drug Osilodrostat Phosphate targets the gene CYP11B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%osilodrostat phosphate%" OR LOWER(tradeNames_string) LIKE "%osilodrostat phosphate%" OR LOWER(drugSynonyms_string) LIKE "%osilodrostat phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5216', 'drugName': 'Osilodrostat Phosphate', 'tradeNames_string': 'Isturisa', 'drugSynonyms_string': 'LCI699-AZA, Osilodrostat phosphate', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110)", 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.452 | Q17 | What gene does the drug Alpelisib target? | The drug Alpelisib targets the gene PIK3CA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%alpelisib%" OR LOWER(tradeNames_string) LIKE "%alpelisib%" OR LOWER(drugSynonyms_string) LIKE "%alpelisib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_722', 'drugName': 'Alpelisib', 'tradeNames_string': 'Piqray, Vijoice', 'drugSynonyms_string': 'Alpelisib, BYL-719, BYL719, Byl-719, NVP-BYL719, Vijoice', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Liver Disease (EFO_0001421), Upper Aerodigestive Tract Neoplasm (EFO_0004284), Gastrointestinal Stromal Tumor (MONDO_0011719), Endometrial Cancer (MONDO_0011962), Colorectal Carcinoma (EFO_1001951), Gastric Cancer (MONDO_0001056), Ovarian Cancer (MONDO_0008170), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Pancreatic Carcinoma (EFO_0002618), Oropharynx Cancer (EFO_1001931), Oropharynx Squamous Cell Carcinoma (MONDO_0044704), Rectum Cancer (EFO_1000657), Squamous Cell Carcinoma (EFO_0000707), Esophageal Squamous Cell Carcinoma (EFO_0005922), Neoplasm (EFO_0000616), Meningioma (MONDO_0016642)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PIK3CA (ENSG00000121879)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1148 | Q17 | What gene does the drug Istradefylline target? | The drug Istradefylline targets the gene ADORA2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%istradefylline%" OR LOWER(tradeNames_string) LIKE "%istradefylline%" OR LOWER(drugSynonyms_string) LIKE "%istradefylline%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2983', 'drugName': 'Istradefylline', 'tradeNames_string': 'Nourianz', 'drugSynonyms_string': 'Istradefylline, KW-6002, Nouriast', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180), Liver Disease (EFO_0001421), Drug Dependence (EFO_0003890), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.865 | Q17 | What gene does the drug Tarloxotinib target? | The drug Tarloxotinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: ERBB3, ERBB2, ERBB4 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tarloxotinib%" OR LOWER(tradeNames_string) LIKE "%tarloxotinib%" OR LOWER(drugSynonyms_string) LIKE "%tarloxotinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_418', 'drugName': 'Tarloxotinib', 'tradeNames_string': '', 'drugSynonyms_string': 'Tarloxotinib, Tarloxotinib cation, Tarloxotinib ion', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1233 | Q17 | What gene does the drug Avapritinib target? | The drug Avapritinib targets 2 genes: PDGFRA and KIT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%avapritinib%" OR LOWER(tradeNames_string) LIKE "%avapritinib%" OR LOWER(drugSynonyms_string) LIKE "%avapritinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3139', 'drugName': 'Avapritinib', 'tradeNames_string': 'Ayvakit', 'drugSynonyms_string': '70C366, Avapritinib, BLU-285, C-366, X-720776, X720776', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Systemic Mastocytosis (MONDO_0016586), Mast-Cell Leukemia (EFO_0007359)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3140', 'drugName': 'Avapritinib', 'tradeNames_string': 'Ayvakit', 'drugSynonyms_string': '70C366, Avapritinib, BLU-285, C-366, X-720776, X720776', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Neoplasm (EFO_0000616), Gastrointestinal Stromal Tumor (MONDO_0011719), Central Nervous System Cancer (EFO_0000326), Systemic Mastocytosis (MONDO_0016586), Mast-Cell Leukemia (EFO_0007359)', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853), KIT (ENSG00000157404)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.100 | Q17 | What gene does the drug Vicriviroc Maleate target? | The drug Vicriviroc Maleate is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CCR5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vicriviroc maleate%" OR LOWER(tradeNames_string) LIKE "%vicriviroc maleate%" OR LOWER(drugSynonyms_string) LIKE "%vicriviroc maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1086', 'drugName': 'Vicriviroc Maleate', 'tradeNames_string': '', 'drugSynonyms_string': 'MK-4176, SCH 417690, SCH-417690, Sch417690, Vicriviroc maleate', 'linkedDiseasesDrug_string': 'Hiv Infection (EFO_0000764)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CCR5 (ENSG00000160791)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1974 | Q17 | What gene does the drug Pentobarbital Sodium target? | The drug Pentobarbital Sodium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentobarbital sodium%" OR LOWER(tradeNames_string) LIKE "%pentobarbital sodium%" OR LOWER(drugSynonyms_string) LIKE "%pentobarbital sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_757', 'drugName': 'Pentobarbital Sodium', 'tradeNames_string': 'Beuthanasia, Euthanase, Euthatal, Nembutal, Nembutal sodium, Pentobarbital sodium, Pentobarbitone Sodium, Sagatal, Sodium pentobarbital', 'drugSynonyms_string': 'Auropan, Barpental, Biosedan, Diabutal, Embutal, Entobar, Etaminal sodium, Ethaminal sodium, Euthanyl, Euthatal, Isobarb, Mebubarbital sodium, Mebumal sodium, NSC-10816, Napental, Narcoren, Pacifan, Pental, Pentobarbital sodium, Pentobarbital sodium salt, Pentobarbitone sodium, Pentonal, Pentone, Praecicalm, Rs-pentobarbital sodium, Sagatal, Sodium ethaminal, Sodium nembutal, Sodium pental, Sodium pentobarbitone, Sodium pentobarbiturate, Sodium-pent, Soluble pentobarbital, Somnopentyl, Somnotol, Sopental, Sotyl, V-pento, Vetbutal', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1973, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.744 | Q17 | What gene does the drug Suloctidil target? | The drug Suloctidil targets 26 genes: CACNA1C, CACNA1H, CACNG2, CACNG7, CACNA2D1, CACNG6, CACNA1B, CACNG5, CACNG3, CACNG1, CACNB3, CACNB4, CACNA1S, CACNA2D3, CACNA1A, CACNA2D4, CACNA1D, CACNB2, CACNA1G, CACNA1I, CACNG8, CACNB1, CACNG4, CACNA1E, CACNA2D2 and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%suloctidil%" OR LOWER(tradeNames_string) LIKE "%suloctidil%" OR LOWER(drugSynonyms_string) LIKE "%suloctidil%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1799', 'drugName': 'Suloctidil', 'tradeNames_string': '', 'drugSynonyms_string': 'Bemperil, CP-556S, Cerebro, Circleton, Dulasi, Duloctil, Euvasal, Fluversin, Fluvisco, Hemoantin, Iangene, Loctidon, Locton, MJF 12637, MJF-12637, Octamet, Polivasal, Sudil, Suloctidil, Sulocton, Sulodene', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1H (ENSG00000196557), CACNA2D1 (ENSG00000153956), CACNA1C (ENSG00000151067), CACNA2D3 (ENSG00000157445), CACNA1S (ENSG00000081248), CACNA2D2 (ENSG00000007402), CACNA1D (ENSG00000157388), CACNA1A (ENSG00000141837), CACNA1B (ENSG00000148408), CACNA1G (ENSG00000006283), CACNA2D4 (ENSG00000151062), CACNA1I (ENSG00000100346), CACNA1F (ENSG00000102001), CACNA1E (ENSG00000198216), CACNB4 (ENSG00000182389), CACNB2 (ENSG00000165995), CACNB1 (ENSG00000067191), CACNB3 (ENSG00000167535), CACNG7 (ENSG00000105605), CACNG5 (ENSG00000075429), CACNG2 (ENSG00000166862), CACNG4 (ENSG00000075461), CACNG8 (ENSG00000142408), CACNG3 (ENSG00000006116), CACNG6 (ENSG00000130433), CACNG1 (ENSG00000108878)', 'numberLinkedTargets': 26}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1252 | Q17 | What gene does the drug Myrcludex B target? | The drug Myrcludex B is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC10A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%myrcludex b%" OR LOWER(tradeNames_string) LIKE "%myrcludex b%" OR LOWER(drugSynonyms_string) LIKE "%myrcludex b%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5546', 'drugName': 'Myrcludex B', 'tradeNames_string': '', 'drugSynonyms_string': 'Hbvpres2-48myr, Myrcludex b', 'linkedDiseasesDrug_string': 'Hepatitis B Virus Infection (EFO_0004197), Hepatitis D Virus Infection (EFO_0007304), Chronic Hepatitis B Virus Infection (EFO_0004239)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC10A1 (ENSG00000100652)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.105 | Q17 | What gene does the drug Caffeine target? | The drug Caffeine targets 4 genes: ADORA1, ADORA3, ADORA2B and ADORA2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%caffeine%" OR LOWER(tradeNames_string) LIKE "%caffeine%" OR LOWER(drugSynonyms_string) LIKE "%caffeine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4744', 'drugName': 'Caffeine', 'tradeNames_string': 'Nodoz, Nodoz caplets and chewable tablets, Pro-plus, Yeast-vite, Zanthine', 'drugSynonyms_string': 'Anhydrous caffeine, Cafcit, Caffeine, Caffeine anhydrous, Caffeine melting point standard, Caffeinum, Coffeine, Coffeinum, Durvitan, FEMA NO. 2224, Guaranine, Methyltheobromine, NSC-5036, Synalgos, Theine, Vivarin', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Toothache (EFO_0010072), Orthostatic Hypotension (EFO_0005252), Coronary Artery Disease (EFO_0001645), Alzheimer Disease (MONDO_0004975), Migraine Without Aura (MONDO_0100431), Liver Disease (EFO_0001421), Pain (EFO_0003843), Infectious Disease (EFO_0005741), Migraine Disorder (MONDO_0005277), Obesity (EFO_0001073), Dysmenorrhea (HP_0100607), Encephalopathy (HP_0001298), Metastatic Melanoma (EFO_0002617), Ulcerative Colitis (EFO_0000729), Spinal Cord Injury (EFO_1001919), Breast Carcinoma (EFO_0000305), Atrial Fibrillation (EFO_0000275), Headache (HP_0002315), Apnea (HP_0002104), Crohn'S Disease (EFO_0000384), Prostate Cancer (MONDO_0008315), Migraine With Aura (MONDO_0005475), Atopic Eczema (EFO_0000274), Non-Alcoholic Steatohepatitis (EFO_1001249), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Brain Ischemia (MONDO_0005299), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Mitochondrial Disease (MONDO_0044970), Tension-Type Headache (HP_0012228), Amblyopia (MONDO_0001020), Ileus (MONDO_0004567), Retinopathy Of Prematurity (EFO_1001158), Memory Impairment (EFO_0001072), Common Cold (EFO_0007214), Neck Pain (HP_0030833), Premature Birth (EFO_0003917), Anemia (Phenotype) (EFO_0004272), Serum Lipopolysaccharide Activity (EFO_0600064), Narcolepsy (MONDO_0021107), Back Pain (HP_0003418), Substance Dependence (MONDO_0004938), Chronic Hepatitis C Virus Infection (EFO_0004220), Rheumatoid Arthritis (EFO_0000685), Alcohol Dependence (MONDO_0007079), Dyspnea (HP_0002094), Hiv Infection (EFO_0000764), Intermittent Vascular Claudication (EFO_0003876), Amyotrophic Lateral Sclerosis (MONDO_0004976), Neoplasm (EFO_0000616), Voice Disorders (EFO_0009692), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Type 2 Diabetes Mellitus (MONDO_0005148), Hypoxia (EFO_0009444)", 'yearOfFirstApproval': 1948, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6075', 'drugName': 'Caffeine, Citrated', 'tradeNames_string': 'Cafcit, Caffeine citrate, Peyona', 'drugSynonyms_string': 'Caffeine citrate, Caffeine mixture with citric acid, Caffeine, citrated, Citrated caffeine', 'linkedDiseasesDrug_string': 'Apnea (HP_0002104), Premature Birth (EFO_0003917), Liver Disease (EFO_0001421), Pain (EFO_0003843), Brain Ischemia (MONDO_0005299), Encephalopathy (HP_0001298), Ileus (MONDO_0004567), Retinopathy Of Prematurity (EFO_1001158)', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADORA1 (ENSG00000163485), ADORA2B (ENSG00000170425), ADORA3 (ENSG00000282608), ADORA2A (ENSG00000128271)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.440 | Q17 | What gene does the drug Mk-0773 target? | The drug Mk-0773 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mk-0773%" OR LOWER(tradeNames_string) LIKE "%mk-0773%" OR LOWER(drugSynonyms_string) LIKE "%mk-0773%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3617', 'drugName': 'Mk-0773', 'tradeNames_string': '', 'drugSynonyms_string': 'Mk-0773, PF-05314882', 'linkedDiseasesDrug_string': 'Sarcopenia (EFO_1000653)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.77 | Q17 | What gene does the drug Setogepram target? | The drug Setogepram is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: GPR84 and FFAR1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%setogepram%" OR LOWER(tradeNames_string) LIKE "%setogepram%" OR LOWER(drugSynonyms_string) LIKE "%setogepram%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4155', 'drugName': 'Setogepram', 'tradeNames_string': '', 'drugSynonyms_string': 'Fezagepras, Pbi-4050, Setogepram', 'linkedDiseasesDrug_string': 'Hyperammonemia (HP_0001987)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FFAR1 (ENSG00000126266), GPR84 (ENSG00000139572)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4156', 'drugName': 'Setogepram', 'tradeNames_string': '', 'drugSynonyms_string': 'Fezagepras, Pbi-4050, Setogepram', 'linkedDiseasesDrug_string': 'Hyperammonemia (HP_0001987)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'FFAR1 (ENSG00000126266), GPR84 (ENSG00000139572)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1793 | Q17 | What gene does the drug Disopyramide target? | The drug Disopyramide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%disopyramide%" OR LOWER(tradeNames_string) LIKE "%disopyramide%" OR LOWER(drugSynonyms_string) LIKE "%disopyramide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2879', 'drugName': 'Disopyramide', 'tradeNames_string': '', 'drugSynonyms_string': '(rs)-disopyramide, Dicorantil, Disopyramide, Dl-disopyramide, H-3292, Isorythm, Lispine, Norpace, Ritmilen, Rythmodan p, SC-7031, Searle-703', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_6051', 'drugName': 'Disopyramide Phosphate', 'tradeNames_string': 'Dirythmin, Dirythmin-sa, Disopyramide phosphate, Isomide cr, Norpace, Norpace cr, Rythmodan ret', 'drugSynonyms_string': 'Dirythmin sa, Diso-duriles, Disopyramide phosphate, NSC-756744, Rythmodan, SC-13957, SC-7031 PHOSPHATE', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269), Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1462 | Q17 | What gene does the drug Asn007 target? | The drug Asn007 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: MAPK3 and MAPK1 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asn007%" OR LOWER(tradeNames_string) LIKE "%asn007%" OR LOWER(drugSynonyms_string) LIKE "%asn007%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5253', 'drugName': 'Asn007', 'tradeNames_string': '', 'drugSynonyms_string': 'ASN007, Asn007, Asn007 rd', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MAPK3 (ENSG00000102882), MAPK1 (ENSG00000100030)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.926 | Q17 | What gene does the drug Amiselimod Hydrochloride target? | The drug Amiselimod Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 5 genes: S1PR3, S1PR4, S1PR5, S1PR1 and S1PR2 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amiselimod hydrochloride%" OR LOWER(tradeNames_string) LIKE "%amiselimod hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%amiselimod hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6385', 'drugName': 'Amiselimod Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Amiselimod hydrochloride, MT-1303', 'linkedDiseasesDrug_string': "Psoriasis (EFO_0000676), Crohn'S Disease (EFO_0000384), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Systemic Lupus Erythematosus (MONDO_0007915), Ulcerative Colitis (EFO_0000729), Inflammatory Bowel Disease (EFO_0003767)", 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1712 | Q17 | What gene does the drug Epacadostat target? | The drug Epacadostat is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene IDO1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epacadostat%" OR LOWER(tradeNames_string) LIKE "%epacadostat%" OR LOWER(drugSynonyms_string) LIKE "%epacadostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_856', 'drugName': 'Epacadostat', 'tradeNames_string': '', 'drugSynonyms_string': 'Epacadostat, INCB-024360, INCB024360', 'linkedDiseasesDrug_string': 'Ovarian Carcinoma (EFO_0001075), Thymic Carcinoma (EFO_1000576), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Gastrointestinal Stromal Tumor (MONDO_0011719), Urothelial Carcinoma (EFO_0008528), Myelodysplastic Syndrome (EFO_0000198), Endometrial Cancer (MONDO_0011962), Ovarian Cancer (MONDO_0008170), Fallopian Tube Carcinoma (EFO_1000251), Lymphoma (EFO_0000574), Pancreatic Ductal Adenocarcinoma (EFO_0002517), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Endometrial Carcinoma (EFO_1001512), Small Cell Lung Carcinoma (EFO_0000702), Renal Cell Carcinoma (EFO_0000681), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Rectum Cancer (EFO_1000657), Urogenital Neoplasm (EFO_0003863), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Metastatic Prostate Cancer (EFO_0000196), Sarcoma (EFO_0000691), Melanoma (EFO_0000756), Glioblastoma Multiforme (EFO_0000519), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'IDO1 (ENSG00000131203)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1671 | Q17 | What gene does the drug Anisindione target? | The drug Anisindione targets the gene GGCX. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%anisindione%" OR LOWER(tradeNames_string) LIKE "%anisindione%" OR LOWER(drugSynonyms_string) LIKE "%anisindione%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1072', 'drugName': 'Anisindione', 'tradeNames_string': 'Miradon', 'drugSynonyms_string': 'Anisindione, NSC-759629', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GGCX (ENSG00000115486)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.